WO2021026180A1 - Solid forms of an hpk1 inhibitor - Google Patents

Solid forms of an hpk1 inhibitor Download PDF

Info

Publication number
WO2021026180A1
WO2021026180A1 PCT/US2020/044919 US2020044919W WO2021026180A1 WO 2021026180 A1 WO2021026180 A1 WO 2021026180A1 US 2020044919 W US2020044919 W US 2020044919W WO 2021026180 A1 WO2021026180 A1 WO 2021026180A1
Authority
WO
WIPO (PCT)
Prior art keywords
salt
compound
acid salt
theta
degrees
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2020/044919
Other languages
English (en)
French (fr)
Inventor
Zhongjiang JIA
William Frietze
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to PE2022000190A priority Critical patent/PE20221419A1/es
Priority to EP20760996.7A priority patent/EP4010338A1/en
Priority to CR20220097A priority patent/CR20220097A/es
Priority to KR1020227007218A priority patent/KR20220059480A/ko
Priority to CA3147918A priority patent/CA3147918A1/en
Priority to CN202080065915.4A priority patent/CN114450276A/zh
Priority to AU2020326703A priority patent/AU2020326703A1/en
Priority to JP2022507441A priority patent/JP2022543155A/ja
Priority to PH1/2022/550271A priority patent/PH12022550271A1/en
Priority to BR112022002059A priority patent/BR112022002059A2/pt
Application filed by Incyte Corp filed Critical Incyte Corp
Priority to MX2022001562A priority patent/MX2022001562A/es
Publication of WO2021026180A1 publication Critical patent/WO2021026180A1/en
Priority to IL289879A priority patent/IL289879A/en
Anticipated expiration legal-status Critical
Priority to CONC2022/0002563A priority patent/CO2022002563A2/es
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/19—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265—Citric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/48—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings
    • C07C59/50—Mandelic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms

Definitions

  • the present invention relates to salt forms of the hematopoietic progenitor kinase 1 (HPK1) inhibitors N-(2-((2S,4S)-4-Amino-2-(hydroxymethyl)pyrrolidin-1-yl)-5- fluorophenyl)-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide and N-(2-((2S,4S)-4- Amino-2-(hydroxymethyl)pyrrolidin-1-yl)-4-(4-cyanopyridin-3-yl)phenyl)-2-(2-fluoro-6- methoxyphenyl)pyrimidine-4-carboxamide, including methods of preparation thereof, wherein the compounds are useful in the treatment of HPK1 mediated diseases such as cancer.
  • HPK1 mediated diseases such as cancer.
  • Hematopoietic progenitor kinase 1 (HPK1) originally cloned from hematopoietic progenitor cells is a member of MAP kinase kinase kinases (MAP4Ks) family, which includes MAP4K1/HPK1, MAP4K2/GCK, MAP4K3/GLK, MAP4K4/HGK, MAP4K5/KHS, and MAP4K6/MINK (Hu, M.C., et al., Genes Dev, 1996.10(18): p.2251-64).
  • MAP4Ks MAP kinase kinase kinases
  • HPK1 is of particular interest because it is predominantly expressed in hematopoietic cells such as T cells, B cells, macrophages, dendritic cells, neutrophils, and mast cells (Hu, M.C., et al., Genes Dev, 1996.10(18): p.2251-64; Kiefer, F., et al., EMBO J, 1996.15(24): p.7013-25).
  • HPK1 kinase activity has been shown to be induced upon activation of T cell receptors (TCR) (Liou, J., et al., Immunity, 2000.12(4): p.399-408), B cell receptors (BCR) (Liou, J., et al., Immunity, 2000.12(4): p.399-408), transforming growth factor receptor (TGF-bR) (Wang, W., et al., J Biol Chem, 1997.272(36): p.22771-5; Zhou, G., et al., J Biol Chem, 1999.274(19): p.13133-8), or Gs-coupled PGE2 receptors (EP2 and EP4) (Ikegami, R., et al., J Immunol, 2001.166(7): p.4689-96).
  • TCR T cell receptors
  • BCR B cell receptors
  • TGF-bR transforming growth factor receptor
  • HPK1 regulates diverse functions of various immune cells.
  • HPK1 is important in regulating the functions of various immune cells and it has been implicated in autoimmune diseases and anti-tumor immunity (Shui, J.W., et al., Nat Immunol, 2007.8(1): p.84-91; Wang, X., et al., J Biol Chem, 2012.287(14): p.11037-48).
  • HPK1 knockout mice were more susceptible to the induction of experimental autoimmune encephalomyelitis (EAE) (Shui, J.W., et al., Nat Immunol, 2007.8(1): p.84-91).
  • HPK1 was downregulated in peripheral blood mononuclear cells of psoriatic arthritis patients or T cells of systemic lupus erythematosus (SLE) patients (Batliwalla, F.M., et al., Mol Med, 2005.11(1-12): p.21-9). Those observations suggested that attenuation of HPK1 activity may contribute to autoimmunity in patients. Furthermore, HPK1 may also control anti-tumor immunity via T cell-dependent mechanisms. In the PGE2-producing Lewis lung carcinoma tumor model, the tumors developed more slowly in HPK1 knockout mice as compared to wild-type mice (see US 2007/0087988).
  • HPK1 is a drug target for enhancing antitumor immunity.
  • Inhibitors of HPK1 are currently being developed for the treatment of cancer.
  • the molecules N-(2-((2S,4S)-4-amino-2-(hydroxymethyl)pyrrolidin-1-yl)-5- fluorophenyl)-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide and N-(2-((2S,4S)-4- amino-2-(hydroxymethyl)pyrrolidin-1-yl)-4-(4-cyanopyridin-3-yl)phenyl)-2-(2-fluoro-6- methoxyphenyl)pyrimidine-4-carboxamide, and other small molecule inhibitors of HPK1 are reported in e.g., US Patent Application No.16/278,865 (published as US Patent Publication No.2019/0382380).
  • the present invention is directed to solid forms of N-(2-((2S,4S)-4-Amino-2- (hydroxymethyl)pyrrolidin-1-yl)-5-fluorophenyl)-2-(2-fluoro-6-methoxyphenyl)pyrimidine- 4-carboxamide (Compound 1) and salts thereof.
  • the present invention is further directed to salts of Compound 1.
  • the present invention is further directed to the phosphoric acid salt of Compound 1, the hydrochloric acid salt of Compound 1, the L-(+)-tartaric acid salt of Compound 1, the malic acid salt of Compound 1, the camphorsulfonic acid salt of Compound 1, the mandelic acid salt of Compound 1, and the citric acid salt of Compound 1.
  • the present invention is directed to solid forms of N-(2-((2S,4S)-4-Amino-2- (hydroxymethyl)pyrrolidin-1-yl)-4-(4-cyanopyridin-3-yl)phenyl)-2-(2-fluoro-6- methoxyphenyl)pyrimidine-4-carboxamide (Compound 2) and salts thereof.
  • the present invention is further directed to salts of Compound 2.
  • the present invention is further directed to the phosphoric acid salt of Compound 2 and the hydrochloric acid salt of Compound 2.
  • the present invention is further directed to crystalline forms of the salts described herein.
  • the present invention is further directed to pharmaceutical compositions comprising a salt or crystalline form described herein, and at least one pharmaceutically acceptable carrier.
  • the present invention is further directed to therapeutic methods of using the salts and solid forms described herein.
  • the present disclosure also provides uses of the salts and solid forms described herein in the manufacture of a medicament for use in therapy.
  • the present disclosure also provides the salts and solid forms described herein for use in therapy.
  • the present invention is further directed to processes for preparing the salts and solid forms described herein.
  • FIG.1 shows an XRPD pattern of Compound 1 Form I.
  • FIG.2 shows a DSC thermogram of Compound 1 Form I.
  • FIG.3 shows a TGA thermogram of Compound 1 Form I.
  • FIG.4 shows an XRPD pattern of Compound 1 phosphate.
  • FIG.5 shows a DSC thermogram of Compound 1 phosphate.
  • FIG.6 shows a TGA thermogram of Compound 1 phosphate.
  • FIG.7 shows an XRPD pattern of Compound 1 hydrochloride.
  • FIG.8 shows a DSC thermogram of Compound 1 hydrochloride.
  • FIG.9 shows a TGA thermogram of Compound 1 hydrochloride.
  • FIG.10 shows an XRPD pattern of Compound 1 L-tartrate.
  • FIG.11 shows a DSC thermogram of Compound 1 L-tartrate.
  • FIG.12 shows a TGA thermogram of Compound 1 L-tartrate.
  • FIG.13 shows an XRPD pattern of Compound 1 malate.
  • FIG.14 shows a DSC thermogram of Compound 1 malate.
  • FIG.15 shows a TGA thermogram of Compound 1 malate.
  • FIG.16 shows an XRPD pattern of Compound 1 camsylate.
  • FIG.17 shows a DSC thermogram of Compound 1 camsylate.
  • FIG.18 shows a TGA thermogram of Compound 1 camsylate.
  • FIG.19 shows an XRPD pattern of Compound 1 mandelate.
  • FIG.20 shows a DSC thermogram of Compound 1 mandelate.
  • FIG.21 shows a TGA thermogram of Compound 1 mandelate.
  • FIG.22 shows an XRPD pattern of Compound 1 citrate.
  • FIG.23 shows a DSC thermogram of Compound 1 citrate.
  • FIG.24 shows a TGA thermogram of Compound 1 citrate.
  • FIG.25 shows an XRPD pattern of Compound 2 phosphate.
  • FIG.26 shows a DSC thermogram of Compound 2 phosphate.
  • FIG.27 shows a TGA thermogram of Compound 2 phosphate.
  • FIG.28 shows an XRPD pattern of Compound 2 hydrochloride.
  • FIG.29 shows a DSC thermogram of Compound 2 hydrochloride.
  • FIG.30 shows a TGA thermogram of Compound 2 hydrochloride.
  • the present invention is directed to, inter alia, solid forms of N-(2-((2S,4S)-4-Amino- 2-(hydroxymethyl)pyrrolidin-1-yl)-5-fluorophenyl)-2-(2-fluoro-6- methoxyphenyl)pyrimidine-4-carboxamide (Compound 1) and salts thereof, the structure of which is shown below.
  • Compound 1 is described in US Patent Application No.16/278,865 (published as US Patent Publication No.2019/0382380), the entirety of which is incorporated herein by reference.
  • Compound 1 and its salts can be isolated as one or more solid forms.
  • the solid forms (e.g., crystalline forms) described herein have many advantages, for example they have desirable properties, such as ease of handling, ease of processing, storage stability, and ease of purification. Moreover, the crystalline forms can be useful for improving the performance characteristics of a pharmaceutical product such as dissolution profile, shelf-life and bioavailability.
  • the citric acid salt of Compound 1 is advantageous because it is highly crystalline, isolable as a single polymorph, non-hygroscopic, stable in aqueous formulations, and can be made reproducibly.
  • the salt of Compound 1 is an acid salt of Compound 1.
  • the acid is selected from phosphoric acid, hydrochloric acid, L-(+)- tartaric acid, malic acid, camphorsulfonic acid, mandelic acid, and citric acid.
  • the salt of the invention is a phosphoric acid salt of Compound 1.
  • the phosphoric acid salt form of Compound 1 is referred to herein as “Compound 1 phosphate salt,” “Compound 1 phosphoric acid salt form,” “Compound 1 phosphoric acid,” or “Compound 1 phosphate.”
  • An alternative name for the salt is N-(2-((2S,4S)-4-Amino-2- (hydroxymethyl)pyrrolidin-1-yl)-5-fluorophenyl)-2-(2-fluoro-6-methoxyphenyl)pyrimidine- 4-carboxamide phosphate.
  • the salt of the invention is a hydrochloric acid salt of Compound 1.
  • the hydrochloric acid salt form of Compound 1 is referred to herein as “Compound 1 hydrochloride salt,” “Compound 1 hydrochloric acid salt form,” “Compound 1 hydrochloric acid,” or “Compound 1 hydrochloride.”
  • An alternative name for the salt is N- (2-((2S,4S)-4-Amino-2-(hydroxymethyl)pyrrolidin-1-yl)-5-fluorophenyl)-2-(2-fluoro-6- methoxyphenyl)pyrimidine-4-carboxamide hydrochloride.
  • the salt of the invention is a L-(+)-tartaric acid salt of Compound 1.
  • the L-(+)-tartaric acid salt form of Compound 1 is referred to herein as “Compound 1 L-tartrate salt,” “Compound 1 L-(+)-tartaric acid salt form,” “Compound 1 L- (+)-tartaric acid,” or “Compound 1 L-tartrate.”
  • An alternative name for the salt is N-(2- ((2S,4S)-4-Amino-2-(hydroxymethyl)pyrrolidin-1-yl)-5-fluorophenyl)-2-(2-fluoro-6- methoxyphenyl)pyrimidine-4-carboxamide L-tartrate.
  • the salt of the invention is a malic acid salt (e.g., L-(-)-malic acid salt) of Compound 1.
  • the malic acid salt form of Compound 1 is referred to herein as “Compound 1 malate salt,” “Compound 1 L-malate salt,” “Compound 1 malic acid salt form,” “Compound 1 malic acid,” “Compound 1 malate,” or “Compound 1 L-malate.”
  • An alternative name for the salt is N-(2-((2S,4S)-4-Amino-2-(hydroxymethyl)pyrrolidin-1-yl)-5- fluorophenyl)-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide malate.
  • the salt of the invention is a camphorsulfonic acid salt of Compound 1.
  • the camphorsulfonic acid salt form of Compound 1 is referred to herein as “Compound 1 camsylate salt,” “Compound 1 camphorsulfonic acid salt form,” “Compound 1 (1S)-(+)-10-camphorsulfonic acid,” “Compound 1 camphorsulfonic acid,” or “Compound 1 camsylate.”
  • An alternative name for the salt is N-(2-((2S,4S)-4-Amino-2- (hydroxymethyl)pyrrolidin-1-yl)-5-fluorophenyl)-2-(2-fluoro-6-methoxyphenyl)pyrimidine- 4-carboxamide camsylate.
  • the salt of the invention is a mandelic acid salt of Compound 1.
  • the mandelic acid salt form of Compound 1 is referred to herein as “Compound 1 mandelate salt,” “Compound 1 mandelic acid salt form,” “Compound 1 mandelic acid,” “Compound 1 (S)-(+)-mandelic acid,” “Compound 1 mandelate,” or “Compound 1 (S)-(+)- mandelate.”
  • An alternative name for the salt is N-(2-((2S,4S)-4-Amino-2- (hydroxymethyl)pyrrolidin-1-yl)-5-fluorophenyl)-2-(2-fluoro-6-methoxyphenyl)pyrimidine- 4-carboxamide mandelate.
  • the salt of the invention is a citric acid salt of Compound 1.
  • the citric acid salt form of Compound 1 is referred to herein as “Compound 1 citrate salt,” “Compound 1 citric acid salt form,” “Compound 1 citric acid,” or “Compound 1 citrate.”
  • An alternative name for the salt is N-(2-((2S,4S)-4-Amino-2-(hydroxymethyl)pyrrolidin-1-yl)-5- fluorophenyl)-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide citrate.
  • the present invention is directed to, inter alia, solid forms of N-(2-((2S,4S)-4-Amino- 2-(hydroxymethyl)pyrrolidin-1-yl)-4-(4-cyanopyridin-3-yl)phenyl)-2-(2-fluoro-6- methoxyphenyl)pyrimidine-4-carboxamide (Compound 2) and salts thereof, the structure of which is shown below.
  • Compound 2 is described in US Patent Application No.16/278,865 (published as US Patent Publication No.2019/0382380), the entirety of which is incorporated herein by reference.
  • Compound 2 and its salts can be isolated as one or more solid forms.
  • the solid forms (e.g., crystalline forms) described herein have many advantages, for example they have desirable properties, such as ease of handling, ease of processing, storage stability, and ease of purification. Moreover, the crystalline forms can be useful for improving the performance characteristics of a pharmaceutical product such as dissolution profile, shelf-life and bioavailability.
  • the phosphoric acid salt of Compound 2 e.g., the dihydrate phosphoric acid salt of Compound 2 is advantageous because it is highly crystalline, isolable as a single polymorph, non-hygroscopic, stable in aqueous formulations, and can be made reproducibly.
  • the salt of Compound 2 is an acid salt of Compound 2.
  • the acid is selected from phosphoric acid and hydrochloric acid.
  • the salt of the invention is a phosphoric acid salt of Compound 2.
  • the phosphoric acid salt form of Compound 2 is referred to herein as “Compound 2 phosphate salt,” “Compound 2 phosphoric acid salt form,” “Compound 2 phosphoric acid,” or “Compound 2 phosphate.”
  • An alternative name for the salt is N-(2-((2S,4S)-4-Amino-2- (hydroxymethyl)pyrrolidin-1-yl)-4-(4-cyanopyridin-3-yl)phenyl)-2-(2-fluoro-6- methoxyphenyl)pyrimidine-4-carboxamide phosphate.
  • the salt of the invention is a hydrochloric acid salt of Compound 2.
  • the hydrochloric acid salt form of Compound 2 is referred to herein as “Compound 2 hydrochloride salt,” “Compound 2 hydrochloric acid salt form,” “Compound 2 hydrochloric acid,” or “Compound 2 hydrochloride.”
  • An alternative name for the salt is N- (2-((2S,4S)-4-Amino-2-(hydroxymethyl)pyrrolidin-1-yl)-4-(4-cyanopyridin-3-yl)phenyl)-2- (2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide hydrochloride.
  • the salts of the invention can be isolated as one or more solid forms.
  • solid form refers to a salt of the invention in either an amorphous state or a crystalline state (“crystalline form” or “crystalline solid”), whereby a salt of the invention in a crystalline state may optionally include solvent or water within the crystalline lattice, for example, to form a solvated or hydrated crystalline form.
  • the salt of the present invention is in a crystalline state as described herein.
  • the term “hydrated,” as used herein, is meant to refer to a crystalline form that includes one or more water molecules in the crystalline lattice.
  • Example “hydrated” crystalline forms include hemihydrates, monohydrates, dihydrates, and the like.
  • salts of the invention can be prepared by any suitable method for the preparation of acid addition salts.
  • the free base of a compound e.g., Compound 1 or Compound 2
  • an acid addition salt of a compound can be converted to a different acid addition salt by anion exchange.
  • Salts of the invention which are prepared in a solvent system can be isolated by precipitation from the solvent. Precipitation and/or crystallization can be induced, for example, by evaporation, reduction of temperature, addition of anti- solvent, or combinations thereof.
  • the salts of the invention are crystalline, including crystalline forms which are anhydrous, hydrated, non-solvated, or solvated.
  • Example hydrates include hemihydrates, monohydrates, dihydrates, and the like.
  • the crystalline salts are anhydrous and non-solvated.
  • anhydrous is meant that the crystalline salt contains no bound water in the crystal lattice structure, i.e., the compound does not form a crystalline hydrate.
  • the salts of the invention are substantially isolated.
  • substantially isolated is meant that the salt is at least partially or substantially separated from the environment in which it was formed or detected. Partial separation can include, for example, a composition enriched in the salt of the invention.
  • Substantial separation can include compositions containing at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% by weight of the salt.
  • the salt forms of the invention were found to be highly crystalline, a desirable property which can facilitate, for example, purification of the drug such as by crystallization and recrystallization as necessary. Further, a crystalline form tends to be more stable and can be easier to mill or micronize when formulating a drug. Crystalline salts also tend have excellent properties with respect to solubility and can be more suitable to be manufactured reproducibly in a clear acid/base ratio, facilitating the preparation of liquid formulations for oral as well as for intravenous applications.
  • crystalline refers to a crystalline solid form of a chemical compound, including, but not limited to, a single-component or multiple- component crystal form, e.g., including solvates, hydrates, clathrates, and a co-crystals.
  • crystalline form is meant to refer to a certain lattice configuration of a crystalline substance. Different crystalline forms of the same substance typically have different crystalline lattices (e.g., unit cells) which are attributed to different physical properties that are characteristic of each of the crystalline forms. In some instances, different lattice configurations have different water or solvent content.
  • the different crystalline lattices can be identified by solid state characterization methods such as by X-ray powder diffraction (XRPD). Other characterization methods such as differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), dynamic vapor sorption (DVS), solid state NMR, and the like further help identify the crystalline form as well as help determine stability and solvent/water content.
  • Crystalline forms of a substance include both solvated (e.g., hydrated) and non- solvated (e.g., anhydrous) forms.
  • a hydrated form is a crystalline form that includes water in the crystalline lattice.
  • Hydrated forms can be stoichiometric hydrates, where the water is present in the lattice in a certain water/molecule ratio such as for hemihydrates, monohydrates, dihydrates, etc. Hydrated forms can also be non-stoichiometric, where the water content is variable and dependent on external conditions such as humidity.
  • substantially crystalline means a majority of the weight of a sample or preparation of a salt (or hydrate or solvate thereof) of the invention is crystalline and the remainder of the sample is a non-crystalline form (e.g., amorphous form) of the same compound.
  • a substantially crystalline sample has at least about 95% crystallinity (e.g., about 5% of the non-crystalline form of the same compound), preferably at least about 96% crystallinity (e.g., about 4% of the non-crystalline form of the same compound), more preferably at least about 97% crystallinity (e.g., about 3% of the non- crystalline form of the same compound), even more preferably at least about 98% crystallinity (e.g., about 2% of the non-crystalline form of the same compound), still more preferably at least about 99% crystallinity (e.g., about 1% of the non-crystalline form of the same compound), and most preferably about 100% crystallinity (e.g., about 0% of the non- crystalline form of the same compound).
  • crystallinity e.g., about 5% of the non-crystalline form of the same compound
  • 96% crystallinity e.g., about 4% of the non-crystalline form of the same compound
  • the term “fully crystalline” means at least about 99% or about 100% crystallinity. Crystalline forms are most commonly characterized by XRPD. An XRPD pattern of reflections (peaks) is typically considered a fingerprint of a particular crystalline form. It is well known that the relative intensities of the XRPD peaks can widely vary depending on, inter alia, the sample preparation technique, crystal size distribution, filters, the sample mounting procedure, and the particular instrument employed. In some instances, new peaks may be observed or existing peaks may disappear, depending on the type of instrument or the settings (for example, whether a Ni filter is used or not).
  • peak refers to a reflection having a relative height/intensity of at least about 4% of the maximum peak height/intensity.
  • instrument variation and other factors can affect the 2-theta values.
  • peak assignments, such as those reported herein can vary by plus or minus about 0.2° (2-theta), and the term “substantially” as used in the context of XRPD herein is meant to encompass the above-mentioned variations.
  • temperature readings in connection with DSC, TGA, or other thermal experiments can vary about ⁇ 3 °C depending on the instrument, particular settings, sample preparation, etc.
  • the temperatures observed will depend on the rate of the temperature change as well as the sample preparation technique and the particular instrument employed.
  • the values reported herein related to DSC thermograms can vary, as indicated above, by ⁇ 3 o C. Accordingly, a crystalline form reported herein having a DSC thermogram “substantially” as shown in any of the Figures is understood to accommodate such variation.
  • the salts and compounds disclosed herein can include all isotopes of atoms occurring within them. Isotopes include those atoms having the same atomic number but different mass numbers. For example, isotopes of hydrogen include tritium and deuterium.
  • Salts and compounds of the invention can also include all isotopes of atoms occurring in the intermediates or final compounds.
  • Isotopes include those atoms having the same atomic number but different mass numbers.
  • isotopes of hydrogen include tritium and deuterium.
  • One or more constituent atoms of the compounds of the invention can be replaced or substituted with isotopes of the atoms in natural or non-natural abundance.
  • the compound includes at least one deuterium atom.
  • one or more hydrogen atoms in a compound of the present disclosure can be replaced or substituted by deuterium.
  • the compound includes two or more deuterium atoms.
  • the compound includes 1, 2, 3, 4, 5, 6, 7 or 8 deuterium atoms.
  • Synthetic methods for including isotopes into organic compounds are known in the art.
  • the term "about”, when used in connection with a numeric value or range of values which is provided to describe a particular solid form e.g., a specific temperature or temperature range, such as describing a melting, dehydration, or glass transition; a mass change, such as a mass change as a function of temperature or humidity; a solvent or water content, in terms of, for example, mass or a percentage; or a peak position, such as in analysis by, for example, 13 C NMR, DSC, TGA and XRPD), indicate that the value or range of values may deviate to an extent deemed reasonable to one of ordinary skill in the art while still describing the particular solid form.
  • the term "about”, when used in this context, indicates that the numeric value or range of values may vary by 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2% or 0.1% of the recited value or range of values while still describing the particular solid form.
  • the term “about”, when used in reference to a degree 2-theta value refers to +/-0.2 degrees 2-theta.
  • melting point refers to an endothermic event or endothermal event observed in e.g., a DSC experiment.
  • An endothermic event is a process or reaction in which a sample absorbs energy from its surrounding in the form of e.g., heat as in a DSC experiment.
  • An exothermic event is a process or reaction in which a sample releases energy.
  • the process of heat absorption and release can be detected by DSC.
  • the term “melting point” is used to describe the major endothermic event revealed on a particular DSC thermogram.
  • room temperature as used herein, is understood in the art, and refers generally to a temperature, e.g., a reaction temperature, that is about the temperature of the room in which the reaction is carried out, for example, a temperature from about 20 oC to about 30 oC.
  • elevated temperature as used herein, is understood in the art, and refer generally to a temperature, e.g., a reaction temperature, that is above room temperature, e.g., above 30 oC.
  • Solid Forms of Compound 1 Compound 1 Form I
  • a solid form of Compound 1 which is crystalline referred to as Form I, which is described below in the Examples.
  • the solvent is a polar solvent.
  • the solvent is C1-6 alkyl alcohol solvent.
  • the solvent is isopropyl alcohol.
  • Form I has at least one characteristic XRPD peak selected from about 6.7, about 9.9, about 13.4, and about 15.5 degrees 2-theta.
  • Form I has at least two characteristic XRPD peaks selected from about 6.7, about 9.9, about 13.4, and about 15.5 degrees 2-theta. In some embodiments, Form I has at least three characteristic XRPD peaks selected from about 6.7, about 9.9, about 13.4, and about 15.5 degrees 2-theta. In some embodiments, Form I has a XRPD peak at about 6.7 degrees 2-theta. In some embodiments, Form I has a XRPD peak at about 9.9 degrees 2-theta. In some embodiments, Form I has a XRPD peak at about 13.4 degrees 2-theta. In some embodiments, Form I has a XRPD peak at about 15.5 degrees 2-theta.
  • Form I has at least one characteristic XRPD peak selected from about 6.7, about 9.9, about 13.4, about 14.1, about 15.5, about 18.3, about 19.9, and about 20.4 degrees 2-theta. In some embodiments, Form I has at least two characteristic XRPD peaks selected from about 6.7, about 9.9, about 13.4, about 14.1, about 15.5, about 18.3, about 19.9, and about 20.4 degrees 2-theta. In some embodiments, Form I has at least three characteristic XRPD peaks selected from about 6.7, about 9.9, about 13.4, about 14.1, about 15.5, about 18.3, about 19.9, and about 20.4 degrees 2-theta.
  • Form I has at least one characteristic XRPD peak selected from about 6.7, about 9.9, about 13.4, about 14.1, about 14.6, about 15.5, about 18.3, about 19.9, about 20.4, about 21.0, about 22.8, and about 25.5 degrees 2-theta. In some embodiments, Form I has at least two characteristic XRPD peaks selected from about 6.7, about 9.9, about 13.4, about 14.1, about 14.6, about 15.5, about 18.3, about 19.9, about 20.4, about 21.0, about 22.8, and about 25.5 degrees 2-theta.
  • Form I has at least three characteristic XRPD peaks selected from about 6.7, about 9.9, about 13.4, about 14.1, about 14.6, about 15.5, about 18.3, about 19.9, about 20.4, about 21.0, about 22.8, and about 25.5 degrees 2-theta.
  • Form I has an XRPD pattern with characteristic peaks as substantially shown in FIG.1.
  • Form I exhibits a DSC thermogram having endotherm peaks at temperatures of about 86 oC and about 183 oC.
  • Form I exhibits a DSC thermogram having an endotherm peak at a temperature of about 86 oC.
  • Form I exhibits a DSC thermogram having an endotherm peak at a temperature of about 183 oC. In some embodiments, Form I has a DSC thermogram substantially as depicted in FIG.2. In some embodiments, Form I has a TGA thermogram substantially as depicted in FIG.3. In some embodiments, Form I has at least one characteristic XRPD peak selected from about 6.7, about 9.9, about 13.4, and about 15.5 degrees 2-theta; and Form I exhibits a DSC thermogram having endotherm peaks at temperatures of about 86 oC and about 183 oC.
  • Form I has at least one characteristic XRPD peak selected from about 6.7, about 9.9, about 13.4, and about 15.5 degrees 2-theta; and Form I exhibits a DSC thermogram having an endotherm peak at a temperatures of about 86 oC. In some embodiments, Form I has at least one characteristic XRPD peak selected from about 6.7, about 9.9, about 13.4, and about 15.5 degrees 2-theta; and Form I exhibits a DSC thermogram having an endotherm peak at a temperatures of about 183 oC. In some embodiments, Form I can be isolated with a purity of at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%.
  • Form I can be isolated with a purity greater than about 99%.
  • Phosphoric acid salts The phosphoric acid salt of Compound 1 can be prepared by any suitable method for preparation of phosphoric acid addition salts.
  • Compound 1 can be combined with phosphoric acid (e.g., about 1.0 molar eq or more) in a solvent and the resulting salt can be isolated by filtering the salt from solution.
  • Compound 1 is combined with about 1 to about 2 molar equivalents of phosphoric acid.
  • Compound 1 is combined with about 1 to about 1.5 molar equivalents of phosphoric acid.
  • Compound 1 is combined with about 1.05 molar equivalents of phosphoric acid.
  • the solvent is a polar solvent. In some embodiments, the solvent is a C1-6 alkyl alcohol. In some embodiments, the solvent is methanol.
  • the phosphoric acid salt of Compound 1 can be crystallized to provide a crystalline solid form. In some embodiments, the crystallization of the phosphoric acid salt of Compound 1 comprises precipitating the phosphoric acid salt of Compound 1 from a crystallizing solvent. In some embodiments, the crystallizing solvent is a polar solvent. In some embodiments, the crystallizing solvent is water. In some embodiments, the phosphoric acid salt of Compound 1 has at least one characteristic XRPD peak selected from about 6.4, about 7.0, about 11.2, and about 12.5 degrees 2-theta.
  • the phosphoric acid salt of Compound 1 has at least two characteristic XRPD peaks selected from about 6.4, about 7.0, about 11.2, and about 12.5 degrees 2-theta. In some embodiments, the phosphoric acid salt of Compound 1 has at least three characteristic XRPD peaks selected from about 6.4, about 7.0, about 11.2, and about 12.5 degrees 2-theta. In some embodiments, the phosphoric acid salt of Compound 1 has a characteristic XRPD peak at about 6.4 degrees 2-theta. In some embodiments, the phosphoric acid salt of Compound 1 has a characteristic XRPD peak at about 7.0 degrees 2-theta.
  • the phosphoric acid salt of Compound 1 has a characteristic XRPD peak at about 11.2 degrees 2-theta. In some embodiments, the phosphoric acid salt of Compound 1 has a characteristic XRPD peak at about 12.5 degrees 2-theta. In some embodiments, the phosphoric acid salt of Compound 1 has at least one characteristic XRPD peak selected from about 6.3, about 6.4, about 7.0, about 8.9, about 11.2, about 12.5, about 19.9, and about 22.9 degrees 2-theta.
  • the phosphoric acid salt of Compound 1 has at least two characteristic XRPD peaks selected from about 6.3, about 6.4, about 7.0, about 8.9, about 11.2, about 12.5, about 19.9, and about 22.9 degrees 2-theta. In some embodiments, the phosphoric acid salt of Compound 1 has at least three characteristic XRPD peaks selected from about 6.3, about 6.4, about 7.0, about 8.9, about 11.2, about 12.5, about 19.9, and about 22.9 degrees 2-theta.
  • the phosphoric acid salt of Compound 1 has at least one characteristic XRPD peak selected from about 6.3, about 6.4, about 7.0, about 8.9, about 11.2, about 12.5, about 15.8, about 17.0, about 18.0, about 19.9, about 22.9, about 24.5, and about 25.2 degrees 2-theta. In some embodiments, the phosphoric acid salt of Compound 1 has at least two characteristic XRPD peaks selected from about 6.3, about 6.4, about 7.0, about 8.9, about 11.2, about 12.5, about 15.8, about 17.0, about 18.0, about 19.9, about 22.9, about 24.5, and about 25.2 degrees 2-theta.
  • the phosphoric acid salt of Compound 1 has at least three characteristic XRPD peaks selected from about 6.3, about 6.4, about 7.0, about 8.9, about 11.2, about 12.5, about 15.8, about 17.0, about 18.0, about 19.9, about 22.9, about 24.5, and about 25.2 degrees 2-theta.
  • the phosphoric acid salt of Compound 1 has an XRPD pattern with characteristic peaks as substantially shown in FIG.4.
  • the phosphoric acid salt of Compound 1 exhibits a DSC thermogram having endothermic peaks at temperatures of about 92 oC and about 229 oC.
  • the phosphoric acid salt of Compound 1 exhibits a DSC thermogram having an endothermic peak at a temperature of about 92 oC. In some embodiments, the phosphoric acid salt of Compound 1 exhibits a DSC thermogram having an endothermic peak at a temperature of about 229 oC. In some embodiments, the phosphoric acid salt of Compound 1 has a DSC thermogram substantially as depicted in FIG.5. In some embodiments, the phosphoric acid salt of Compound 1 has a TGA thermogram substantially as depicted in FIG.6.
  • the phosphoric acid salt of Compound 1 has at least one characteristic XRPD peak selected from about 6.4, about 7.0, about 11.2, and about 12.5 degrees 2-theta; and the phosphoric acid salt exhibits a DSC thermogram having endothermic peaks at temperatures of about 92 oC and about 229 oC. In some embodiments, the phosphoric acid salt of Compound 1 has at least one characteristic XRPD peak selected from about 6.4, about 7.0, about 11.2, and about 12.5 degrees 2-theta; and the phosphoric acid salt exhibits a DSC thermogram having an endothermic peak at a temperature of about 92 oC.
  • the phosphoric acid salt of Compound 1 has at least one characteristic XRPD peak selected from about 6.4, about 7.0, about 11.2, and about 12.5 degrees 2-theta; and the phosphoric acid salt exhibits a DSC thermogram having an endothermic peak at a temperature of about 229 oC.
  • the phosphoric acid salt of Compound 1 is substantially crystalline.
  • the salt is crystalline. Hydrochloric acid salts
  • the hydrochloric acid salt of Compound 1 can be prepared by any suitable method for preparation of hydrochloric acid addition salts.
  • Compound 1 can be combined with hydrochloric acid (e.g., about 1.0 molar eq or more) in a solvent and the resulting salt can be isolated by filtering the salt from solution.
  • hydrochloric acid e.g., about 1.0 molar eq or more
  • Compound 1 is combined with about 1 to about 2 molar equivalents of hydrochloric acid.
  • Compound 1 is combined with about 1 to about 1.5 molar equivalents of hydrochloric acid.
  • Compound 1 is combined with about 1.05 molar equivalents of hydrochloric acid.
  • the solvent is a polar solvent.
  • the solvent is a C1-6 alkyl alcohol.
  • the solvent is methanol.
  • the hydrochloric acid salt of Compound 1 can be crystallized to provide a crystalline solid form.
  • the crystallization of the hydrochloric acid salt of Compound 1 comprises precipitating the hydrochloric acid salt of Compound 1 from a crystallizing solvent.
  • the crystallizing solvent is a polar solvent.
  • the crystallizing solvent is water.
  • the hydrochloric acid salt of Compound 1 has at least one characteristic XRPD peak selected from about 6.7, about 9.1, about 13.5, and about 15.5 degrees 2-theta.
  • the hydrochloric acid salt of Compound 1 has at least two characteristic XRPD peaks selected from about 6.7, about 9.1, about 13.5, and about 15.5 degrees 2-theta. In some embodiments, the hydrochloric acid salt of Compound 1 has at least three characteristic XRPD peaks selected from about 6.7, about 9.1, about 13.5, and about 15.5 degrees 2-theta. In some embodiments, the hydrochloric acid salt of Compound 1 has a characteristic XRPD peak at about 6.7 degrees 2-theta. In some embodiments, the hydrochloric acid salt of Compound 1 has a characteristic XRPD peak at about 9.1 degrees 2- theta.
  • the hydrochloric acid salt of Compound 1 has a characteristic XRPD peak at about 13.5 degrees 2-theta. In some embodiments, the hydrochloric acid salt of Compound 1 has a characteristic XRPD peak at about 15.5 degrees 2-theta. In some embodiments, the hydrochloric acid salt of Compound 1 has at least one characteristic XRPD peak selected from about 6.7, about 9.1, about 11.0, about 12.7, about 13.5, about 15.5, about 17.1, and about 23.4 degrees 2-theta.
  • the hydrochloric acid salt of Compound 1 has at least two characteristic XRPD peaks selected from about 6.7, about 9.1, about 11.0, about 12.7, about 13.5, about 15.5, about 17.1, and about 23.4 degrees 2-theta. In some embodiments, the hydrochloric acid salt of Compound 1 has at least three characteristic XRPD peaks selected from about 6.7, about 9.1, about 11.0, about 12.7, about 13.5, about 15.5, about 17.1, and about 23.4 degrees 2-theta.
  • the hydrochloric acid salt of Compound 1 has at least one characteristic XRPD peak selected from about 4.5, about 6.0, about 6.7, about 9.1, about 10.6, about 11.0, about 12.7, about 13.5, about 15.5, about 17.1, about 18.2, about 21.2, about 22.7, and about 23.4 degrees 2-theta. In some embodiments, the hydrochloric acid salt of Compound 1 has at least two characteristic XRPD peaks selected from about 4.5, about 6.0, about 6.7, about 9.1, about 10.6, about 11.0, about 12.7, about 13.5, about 15.5, about 17.1, about 18.2, about 21.2, about 22.7, and about 23.4 degrees 2-theta.
  • the hydrochloric acid salt of Compound 1 has at least three characteristic XRPD peaks selected from about 4.5, about 6.0, about 6.7, about 9.1, about 10.6, about 11.0, about 12.7, about 13.5, about 15.5, about 17.1, about 18.2, about 21.2, about 22.7, and about 23.4 degrees 2- theta.
  • the hydrochloric acid salt of Compound 1 has an XRPD pattern with characteristic peaks as substantially shown in FIG.7.
  • the hydrochloric acid salt of Compound 1 exhibits a DSC thermogram having endothermic peaks at temperatures of about 107 oC and about 233 oC.
  • the hydrochloric acid salt of Compound 1 exhibits a DSC thermogram having an endothermic peak at a temperature of about 107 oC. In some embodiments, the hydrochloric acid salt of Compound 1 exhibits a DSC thermogram having an endothermic peak at a temperature of about 233 oC. In some embodiments, the hydrochloric acid salt of Compound 1 has a DSC thermogram substantially as depicted in FIG.8. In some embodiments, the hydrochloric acid salt h of Compound 1 as a TGA thermogram substantially as depicted in FIG.9.
  • the hydrochloric acid salt of Compound 1 has at least one characteristic XRPD peak selected from about 6.7, about 9.1, about 13.5, and about 15.5 degrees 2-theta; and the hydrochloric acid salt exhibits a DSC thermogram having endothermic peaks at temperatures of about 107 oC and about 233 oC. In some embodiments, the hydrochloric acid salt of Compound 1 has at least one characteristic XRPD peak selected from about 6.7, about 9.1, about 13.5, and about 15.5 degrees 2-theta; and the hydrochloric acid salt exhibits a DSC thermogram having an endothermic peak at a temperature of about 107 oC.
  • the hydrochloric acid salt of Compound 1 has at least one characteristic XRPD peak selected from about 6.7, about 9.1, about 13.5, and about 15.5 degrees 2-theta; and the hydrochloric acid salt exhibits a DSC thermogram having an endothermic peak at a temperature of about 233 oC.
  • the hydrochloric acid salt of Compound 1 is substantially crystalline.
  • the salt is crystalline. L-(+)-Tartaric acid salts
  • the L-(+)-tartaric acid salt of Compound 1 can be prepared by any suitable method for preparation of L-(+)-tartaric acid addition salts.
  • Compound 1 can be combined with L-(+)-tartaric acid (e.g., about 1.0 molar eq or more) in a solvent and the resulting salt can be isolated by filtering the salt from solution.
  • Compound 1 is combined with about 1 to about 2 molar equivalents of L-(+)-tartaric acid.
  • Compound 1 is combined with about 1 to about 1.5 molar equivalents of L-(+)-tartaric acid.
  • Compound 1 is combined with about 1.15 molar equivalents of L-(+)-tartaric acid.
  • the solvent is a polar solvent.
  • the solvent is a C1-6 alkyl alcohol.
  • the solvent is methanol.
  • the L-(+)-tartaric acid salt of Compound 1 can be crystallized to provide a crystalline solid form.
  • the crystallization of the L-(+)-tartaric acid salt of Compound 1 comprises precipitating the L-(+)-tartaric acid salt of Compound 1 from a crystallizing solvent.
  • the crystallizing solvent is a polar solvent.
  • the crystallizing solvent is water.
  • the L-(+)-tartaric acid salt of Compound 1 has at least one characteristic XRPD peak selected from about 4.9, about 7.9, and about 9.8 degrees 2-theta.
  • the L-(+)-tartaric acid salt of Compound 1 has at least two characteristic XRPD peaks selected from about 4.9, about 7.9, and about 9.8 degrees 2-theta. In some embodiments, the L-(+)-tartaric acid salt of Compound 1 has three characteristic XRPD peaks selected from about 4.9, about 7.9, and about 9.8 degrees 2-theta. In some embodiments, the L-(+)-tartaric acid salt of Compound 1 has a characteristic XRPD peak at about 4.9 degrees 2-theta. In some embodiments, the L-(+)-tartaric acid salt of Compound 1 has a characteristic XRPD peak at about 7.9 degrees 2-theta.
  • the L- (+)-tartaric acid salt of Compound 1 has a characteristic XRPD peak at about 9.8 degrees 2- theta. In some embodiments, the L-(+)-tartaric acid salt of Compound 1 has at least one characteristic XRPD peak selected from about 4.9, about 7.9, about 9.8, about 15.9, about 16.9, about 19.6, and about 23.0 degrees 2-theta. In some embodiments, the L-(+)-tartaric acid salt of Compound 1 has at least two characteristic XRPD peaks selected from about 4.9, about 7.9, about 9.8, about 15.9, about 16.9, about 19.6, and about 23.0 degrees 2-theta.
  • the L-(+)-tartaric acid salt of Compound 1 has at least three characteristic XRPD peaks selected from about 4.9, about 7.9, about 9.8, about 15.9, about 16.9, about 19.6, and about 23.0 degrees 2-theta. In some embodiments, the L-(+)-tartaric acid salt of Compound 1 has at least one characteristic XRPD peak selected from about 4.9, about 7.5, about 7.9, about 9.8, about 10.5, about 13.7, about 14.7, about 15.9, about 16.0, about 16.9, about 18.1, about 19.6, about 20.8, about 23.0, and about 24.7 degrees 2-theta.
  • the L-(+)-tartaric acid salt of Compound 1 has at least two characteristic XRPD peaks selected from about 4.9, about 7.5, about 7.9, about 9.8, about 10.5, about 13.7, about 14.7, about 15.9, about 16.0, about 16.9, about 18.1, about 19.6, about 20.8, about 23.0, and about 24.7 degrees 2-theta.
  • the L-(+)-tartaric acid salt of Compound 1 has at least three characteristic XRPD peaks selected from about 4.9, about 7.5, about 7.9, about 9.8, about 10.5, about 13.7, about 14.7, about 15.9, about 16.0, about 16.9, about 18.1, about 19.6, about 20.8, about 23.0, and about 24.7 degrees 2-theta.
  • the L-(+)-tartaric acid salt of Compound 1 has an XRPD pattern with characteristic peaks as substantially shown in FIG.10.
  • the L-(+)-tartaric acid salt of Compound 1 exhibits a DSC thermogram having endothermic peaks at temperatures of about 102 oC and about 217 oC.
  • the endothermic peak is at a temperature of about 102 oC. In some embodiments, the endothermic peak is at a temperature of about 217 oC.
  • the L-(+)-tartaric acid salt of Compound 1 has a DSC thermogram substantially as depicted in FIG.11. In some embodiments, the L-(+)-tartaric acid salt of Compound 1 has a TGA thermogram substantially as depicted in FIG.12.
  • the L-(+)-tartaric acid salt of Compound 1 has at least one characteristic XRPD peak selected from about 4.9, about 7.9, and about 9.8 degrees 2-theta; and the L-(+)-tartaric acid salt exhibits a DSC thermogram having endothermic peaks at temperatures of about 102 oC and about 217 oC.
  • the L-(+)-tartaric acid salt of Compound 1 has at least one characteristic XRPD peak selected from about 4.9, about 7.9, and about 9.8 degrees 2-theta; and the L-(+)-tartaric acid salt exhibits a DSC thermogram having an endothermic peak at a temperature of about 102 oC.
  • the L- (+)-tartaric acid salt of Compound 1 has at least one characteristic XRPD peak selected from about 4.9, about 7.9, and about 9.8 degrees 2-theta; and the L-(+)-tartaric acid salt exhibits a DSC thermogram having an endothermic peak at a temperature of about 217 oC.
  • the L-(+)-tartaric acid salt of Compound 1 is substantially crystalline.
  • the salt is crystalline.
  • Malic acid salts The malic acid salt of Compound 1 can be prepared by any suitable method for preparation of malic acid addition salts.
  • Compound 1 can be combined with L- (-)-malic acid (e.g., about 1.0 molar eq or more) in a solvent and the resulting salt can be isolated by filtering the salt from solution.
  • Compound 1 is combined with about 1 to about 2 molar equivalents of L-(-)-malic acid.
  • Compound 1 is combined with about 1 to about 1.5 molar equivalents of L-(-)-malic acid.
  • Compound 1 is combined with about 1.2 molar equivalents of L-(-)- malic acid.
  • the solvent is a polar solvent.
  • the solvent is a C1-6 alkyl alcohol.
  • the solvent is methanol.
  • the malic acid salt of Compound 1 can be crystallized to provide a crystalline solid form.
  • the crystallization of the malic acid salt of Compound 1 comprises precipitating the malic acid salt of Compound 1 from a crystallizing solvent.
  • the crystallizing solvent is a polar solvent.
  • the solvent is a C1-6 alkyl alcohol.
  • the solvent is methanol.
  • the malic acid salt of Compound 1 has at least one characteristic XRPD peak selected from about 5.2, about 10.4, and about 21.0 degrees 2- theta.
  • the malic acid salt of Compound 1 has at least two characteristic XRPD peaks selected from about 5.2, about 10.4, and about 21.0 degrees 2-theta. In some embodiments, the malic acid salt of Compound 1 has three characteristic XRPD peaks selected from about 5.2, about 10.4, and about 21.0 degrees 2-theta. In some embodiments, the malic acid salt of Compound 1 has a characteristic XRPD peak at about 5.2 degrees 2- theta. In some embodiments, the malic acid salt of Compound 1 has a characteristic XRPD peak at about 10.4 degrees 2-theta. In some embodiments, the malic acid salt of Compound 1 has a characteristic XRPD peak at about 21.0 degrees 2-theta.
  • the malic acid salt of Compound 1 has at least one characteristic XRPD peak selected from about 5.2, about 7.9, about 10.4, about 14.3, about 15.8, about 16.6, about 18.0, about 21.0, and about 21.2 degrees 2-theta. In some embodiments, the malic acid salt of Compound 1 has at least two characteristic XRPD peaks selected from about 5.2, about 7.9, about 10.4, about 14.3, about 15.8, about 16.6, about 18.0, about 21.0, and about 21.2 degrees 2-theta.
  • the malic acid salt of Compound 1 has at least three characteristic XRPD peaks selected from about 5.2, about 7.9, about 10.4, about 14.3, about 15.8, about 16.6, about 18.0, about 21.0, and about 21.2 degrees 2-theta. In some embodiments, the malic acid salt of Compound 1 has at least one characteristic XRPD peak selected from about 5.2, about 7.9, about 8.2, about 10.4, about 14.3, about 15.8, about 16.6, about 18.0, about 19.2, about 21.0, about 21.2, about 25.9 degrees 2-theta.
  • the malic acid salt of Compound 1 has at least two characteristic XRPD peaks selected from about 5.2, about 7.9, about 8.2, about 10.4, about 14.3, about 15.8, about 16.6, about 18.0, about 19.2, about 21.0, about 21.2, about 25.9 degrees 2-theta. In some embodiments, the malic acid salt of Compound 1 has at least three characteristic XRPD peaks selected from about 5.2, about 7.9, about 8.2, about 10.4, about 14.3, about 15.8, about 16.6, about 18.0, about 19.2, about 21.0, about 21.2, about 25.9 degrees 2-theta. In some embodiments, the malic acid salt of Compound 1 has an XRPD pattern with characteristic peaks as substantially shown in FIG.13.
  • the malic acid salt of Compound 1 exhibits a DSC thermogram having endothermic peaks at temperatures of about 71 oC and about 198 oC. In some embodiments, the malic acid salt of Compound 1 exhibits a DSC thermogram having an endothermic peak at a temperature of about 71 oC. In some embodiments, the malic acid salt of Compound 1 exhibits a DSC thermogram having an endothermic peak at a temperature of about 198 oC. In some embodiments, the malic acid salt of Compound 1 has a DSC thermogram substantially as depicted in FIG.14. In some embodiments, the malic acid salt of Compound 1 has a TGA thermogram substantially as depicted in FIG.15.
  • the malic acid salt of Compound 1 has at least one characteristic XRPD peak selected from about 5.2, about 10.4, and about 21.0 degrees 2- theta; and the malic acid salt exhibits a DSC thermogram having endothermic peaks at temperatures of about 71 oC and about 198 oC. In some embodiments, the malic acid salt of Compound 1 has at least one characteristic XRPD peak selected from about 5.2, about 10.4, and about 21.0 degrees 2-theta; and the malic acid salt exhibits a DSC thermogram having an endothermic peak at a temperature of about 71 oC.
  • the malic acid salt of Compound 1 has at least one characteristic XRPD peak selected from about 5.2, about 10.4, and about 21.0 degrees 2-theta; and the malic acid salt exhibits a DSC thermogram having an endothermic peak at a temperature of about 198 oC.
  • the malic acid salt of Compound 1 is substantially crystalline.
  • the salt is crystalline.
  • Camphorsulfonic acid salts The camphorsulfonic acid salt of Compound 1 can be prepared by any suitable method for preparation of camphorsulfonic acid addition salts.
  • Compound 1 can be combined with (1S)-(+)-camphorsulfonic acid (e.g., about 1.0 molar eq or more) in a solvent and the resulting salt can be isolated by filtering the salt from solution.
  • Compound 1 is combined with about 1 to about 2 molar equivalents of (1S)- (+)-camphorsulfonic acid.
  • Compound 1 is combined with about 1 to about 1.5 molar equivalents of (1S)-(+)-camphorsulfonic acid.
  • Compound 1 is combined with about 1.1 molar equivalents of (1S)-(+)-camphorsulfonic acid.
  • the solvent is a polar solvent.
  • the solvent is a C1-6 alkyl alcohol. In some embodiments, the solvent is methanol.
  • the camphorsulfonic acid salt of Compound 1 can be crystallized to provide a crystalline solid form. In some embodiments, the crystallization of the camphorsulfonic acid salt of Compound 1 comprises precipitating the camphorsulfonic acid salt of Compound 1 from a crystallizing solvent. In some embodiments, the crystallizing solvent is a polar solvent. In some embodiments, the solvent is water. In some embodiments, the camphorsulfonic acid salt of Compound 1 has at least one characteristic XRPD peak selected from about 4.9, about 5.9, and about 15.1 degrees 2-theta.
  • the camphorsulfonic acid salt of Compound 1 has at least two characteristic XRPD peaks selected from about 4.9, about 5.9, and about 15.1 degrees 2- theta. In some embodiments, the camphorsulfonic acid salt of Compound 1 has three characteristic XRPD peaks selected from about 4.9, about 5.9, and about 15.1 degrees 2- theta. In some embodiments, the camphorsulfonic acid salt of Compound 1 has a characteristic XRPD peak at about 4.9 degrees 2-theta. In some embodiments, the camphorsulfonic acid salt of Compound 1 has a characteristic XRPD peak at about 5.9 degrees 2-theta.
  • the camphorsulfonic acid salt of Compound 1 has a characteristic XRPD peak at about 15.1 degrees 2-theta. In some embodiments, the camphorsulfonic acid salt of Compound 1 has at least one characteristic XRPD peak selected from about 4.9, about 5.9, about 10.9, about 14.4, about 15.0, about 15.1, about 19.8, about 20.1, and about 25.8 degrees 2-theta. In some embodiments, the camphorsulfonic acid salt of Compound 1 has at least two characteristic XRPD peaks selected from about 4.9, about 5.9, about 10.9, about 14.4, about 15.0, about 15.1, about 19.8, about 20.1, and about 25.8 degrees 2-theta.
  • the camphorsulfonic acid salt of Compound 1 has at least three characteristic XRPD peaks selected from about 4.9, about 5.9, about 10.9, about 14.4, about 15.0, about 15.1, about 19.8, about 20.1, and about 25.8 degrees 2-theta. In some embodiments, the camphorsulfonic acid salt of Compound 1 has at least one characteristic XRPD peak selected about 4.9, about 5.9, about 9.8, about 10.9, about 12.2, about 14.4, about 15.0, about 15.1, about 16.5, about 19.8, about 20.1, about 20.9, and about 25.8 degrees 2-theta.
  • the camphorsulfonic acid salt of Compound 1 has at least two characteristic XRPD peaks selected from about 4.9, about 5.9, about 9.8, about 10.9, about 12.2, about 14.4, about 15.0, about 15.1, about 16.5, about 19.8, about 20.1, about 20.9, and about 25.8 degrees 2-theta. In some embodiments, the camphorsulfonic acid salt of Compound 1 has at least three characteristic XRPD peaks selected from about 4.9, about 5.9, about 9.8, about 10.9, about 12.2, about 14.4, about 15.0, about 15.1, about 16.5, about 19.8, about 20.1, about 20.9, and about 25.8 degrees 2-theta.
  • the camphorsulfonic acid salt of Compound 1 has an XRPD pattern with characteristic peaks as substantially shown in FIG.16. In some embodiments, the camphorsulfonic acid salt of Compound 1 exhibits a DSC thermogram having endothermic peaks at temperatures of about 64 oC and about 236 oC. In some embodiments, the camphorsulfonic acid salt of Compound 1 exhibits a DSC thermogram having an endothermic peak at a temperature of about 64 oC. In some embodiments, the camphorsulfonic acid salt of Compound 1 exhibits a DSC thermogram having an endothermic peak at a temperature of about 236 oC.
  • the camphorsulfonic acid salt of Compound 1 has a DSC thermogram substantially as depicted in FIG.17. In some embodiments, the camphorsulfonic acid salt of Compound 1 has a TGA thermogram substantially as depicted in FIG.18. In some embodiments, the camphorsulfonic acid salt of Compound 1 has at least one characteristic XRPD peak selected from about 4.9, about 5.9, and about 15.1 degrees 2-theta; and the camphorsulfonic acid salt exhibits a DSC thermogram having endothermic peaks at temperatures of about 64 oC and about 236 oC.
  • the camphorsulfonic acid salt of Compound 1 has at least one characteristic XRPD peak selected from about 4.9, about 5.9, and about 15.1 degrees 2-theta; and the camphorsulfonic acid salt exhibits a DSC thermogram having an endothermic peak at a temperature of about 64 oC. In some embodiments, the camphorsulfonic acid salt of Compound 1 has at least one characteristic XRPD peak selected from about 4.9, about 5.9, and about 15.1 degrees 2-theta; and the camphorsulfonic acid salt exhibits a DSC thermogram having an endothermic peak at a temperature of about 236 oC. In some embodiments, the camphorsulfonic acid salt of Compound 1 is substantially crystalline.
  • the salt is crystalline.
  • Mandelic acid salts The mandelic acid salt of Compound 1 can be prepared by any suitable method for preparation of mandelic acid addition salts.
  • Compound 1 can be combined with (S)-(+)-mandelic acid (e.g., about 1.0 molar eq or more) in a solvent and the resulting salt can be isolated by filtering the salt from solution.
  • Compound 1 is combined with about 1 to about 2 molar equivalents of (S)-(+)-mandelic acid.
  • Compound 1 is combined with about 1 to about 1.5 molar equivalents of (S)- (+)-mandelic acid.
  • Compound 1 is combined with about 1.2 molar equivalents of (S)-(+)-mandelic acid.
  • the solvent is a polar solvent.
  • the solvent is a C1-6 alkyl alcohol.
  • the solvent is methanol.
  • the mandelic acid salt of Compound 1 can be crystallized to provide a crystalline solid form.
  • the crystallization of the mandelic acid salt of Compound 1 comprises precipitating the mandelic acid salt of Compound 1 from a crystallizing solvent.
  • the crystallizing solvent is a polar solvent.
  • the solvent is water.
  • the mandelic acid salt of Compound 1 has at least one characteristic XRPD peak selected from about 4.2, about 5.0, about 5.8, and about 6.9 degrees 2-theta. In some embodiments, the mandelic acid salt of Compound 1 has at least two characteristic XRPD peaks selected from about 4.2, about 5.0, about 5.8, and about 6.9 degrees 2-theta. In some embodiments, the mandelic acid salt of Compound 1 has at least three characteristic XRPD peaks selected from about 4.2, about 5.0, about 5.8, and about 6.9 degrees 2-theta. In some embodiments, the mandelic acid salt of Compound 1 has a characteristic XRPD peak at about 4.2 degrees 2-theta.
  • the mandelic acid salt of Compound 1 has a characteristic XRPD peak at about 5.0 degrees 2-theta. In some embodiments, the mandelic acid salt of Compound 1 has a characteristic XRPD peak at about 5.8 degrees 2-theta. In some embodiments, the mandelic acid salt of Compound 1 has a characteristic XRPD peak at about 6.9 degrees 2-theta. In some embodiments, the mandelic acid salt of Compound 1 has at least one characteristic XRPD peak selected from about 4.2, about 5.0, about 5.4, about 5.8, about 6.9, about 14.2, about 15.3, about 19.0, and about 19.6 degrees 2-theta.
  • the mandelic acid salt of Compound 1 has at least two characteristic XRPD peaks selected from about 4.2, about 5.0, about 5.4, about 5.8, about 6.9, about 14.2, about 15.3, about 19.0, and about 19.6 degrees 2-theta. In some embodiments, the mandelic acid salt of Compound 1 has at least three characteristic XRPD peaks selected from about 4.2, about 5.0, about 5.4, about 5.8, about 6.9, about 14.2, about 15.3, about 19.0, and about 19.6 degrees 2-theta.
  • the mandelic acid salt of Compound 1 has at least one characteristic XRPD peak selected about 4.2, about 5.0, about 5.4, about 5.8, about 6.9, about 10.1, about 12.6, about 14.2, about 15.0, about 15.3, about 17.1, about 18.7, about 19.0, and about 19.6 degrees 2-theta. In some embodiments, the mandelic acid salt of Compound 1 has at least two characteristic XRPD peaks selected from about 4.2, about 5.0, about 5.4, about 5.8, about 6.9, about 10.1, about 12.6, about 14.2, about 15.0, about 15.3, about 17.1, about 18.7, about 19.0, and about 19.6 degrees 2-theta.
  • the mandelic acid salt of Compound 1 has at least three characteristic XRPD peaks selected from about 4.2, about 5.0, about 5.4, about 5.8, about 6.9, about 10.1, about 12.6, about 14.2, about 15.0, about 15.3, about 17.1, about 18.7, about 19.0, and about 19.6 degrees 2-theta.
  • the mandelic acid salt of Compound 1 has an XRPD pattern with characteristic peaks as substantially shown in FIG.19.
  • the mandelic acid salt of Compound 1 exhibits a DSC thermogram having endothermic peaks at temperatures of about 93 oC and about 217 oC.
  • the mandelic acid salt of Compound 1 exhibits a DSC thermogram having an endothermic peak at a temperature of about 93 oC. In some embodiments, the mandelic acid salt of Compound 1 exhibits a DSC thermogram having an endothermic peak at a temperature of about 217 oC. In some embodiments, the mandelic acid salt of Compound 1 has a DSC thermogram substantially as depicted in FIG.20. In some embodiments, the mandelic acid salt of Compound 1 has a TGA thermogram substantially as depicted in FIG. 21.
  • the mandelic acid salt of Compound 1 has at least one characteristic XRPD peak selected from about 4.2, about 5.0, about 5.8, and about 6.9 degrees 2-theta; and the mandelic acid salt exhibits a DSC thermogram having endothermic peaks at temperatures of about 93 oC and about 217 oC. In some embodiments, the mandelic acid salt of Compound 1 has at least one characteristic XRPD peak selected from about 4.2, about 5.0, about 5.8, and about 6.9 degrees 2-theta; and the mandelic acid salt exhibits a DSC thermogram having an endothermic peak at a temperature of about 93 oC.
  • the mandelic acid salt of Compound 1 has at least one characteristic XRPD peak selected from about 4.2, about 5.0, about 5.8, and about 6.9 degrees 2-theta; and the mandelic acid salt exhibits a DSC thermogram having an endothermic peak at a temperature of about 217 oC.
  • the mandelic acid salt of Compound 1 is substantially crystalline.
  • the salt is crystalline.
  • Citric acid salts The citric acid salt of Compound 1 can be prepared by any suitable method for preparation of citric acid addition salts.
  • Compound 1 can be combined with citric acid (e.g., about 1.0 molar eq or more) in a solvent and the resulting salt can be isolated by filtering the salt from solution.
  • Compound 1 is combined with about 1 to about 2 molar equivalents of citric acid.
  • Compound 1 is combined with about 1 to about 1.5 molar equivalents of citric acid.
  • Compound 1 is combined with about 1.05 molar equivalents of citric acid.
  • the solvent is a polar solvent.
  • the solvent is a C1-6 alkyl alcohol.
  • the solvent is acetone.
  • the solvent is a mixture of acetone and water.
  • the citric acid salt of Compound 1 can be crystallized to provide a crystalline solid form.
  • the crystallization of the citric acid salt of Compound 1 comprises precipitating the citric acid salt of Compound 1 from a crystallizing solvent.
  • the crystallizing solvent is acetone.
  • the crystallizing solvent is a mixture of acetone and water.
  • the citric acid salt of Compound 1 has at least one characteristic XRPD peak selected from about 7.3, about 9.0, about 13.6, and about 18.3 degrees 2-theta.
  • the citric acid salt of Compound 1 has at least two characteristic XRPD peaks selected from about 7.3, about 9.0, about 13.6, and about 18.3 degrees 2-theta. In some embodiments, the citric acid salt of Compound 1 has at least three characteristic XRPD peaks selected from about 7.3, about 9.0, about 13.6, and about 18.3 degrees 2-theta. In some embodiments, the citric acid salt of Compound 1 has a characteristic XRPD peak at about 7.3 degrees 2-theta. In some embodiments, the citric acid salt of Compound 1 has a characteristic XRPD peak at about 9.0 degrees 2-theta.
  • the citric acid salt of Compound 1 has a characteristic XRPD peak at about 13.6 degrees 2-theta. In some embodiments, the citric acid salt of Compound 1 has a characteristic XRPD peak at about 18.3 degrees 2-theta. In some embodiments, the citric acid salt of Compound 1 has at least one characteristic XRPD peak selected from about 7.3, about 9.0, about 13.6, about 16.6, about 18.1, about 18.3, about 19.5, about 20.1, and about 20.9 degrees 2-theta.
  • the citric acid salt of Compound 1 has at least two characteristic XRPD peaks selected from about 7.3, about 9.0, about 13.6, about 16.6, about 18.1, about 18.3, about 19.5, about 20.1, and about 20.9 degrees 2-theta. In some embodiments, the citric acid salt of Compound 1 has at least three characteristic XRPD peaks selected from about 7.3, about 9.0, about 13.6, about 16.6, about 18.1, about 18.3, about 19.5, about 20.1, and about 20.9 degrees 2-theta.
  • the citric acid salt of Compound 1 has at least one characteristic XRPD peak selected about 7.3, about 9.0, about 13.6, about 13.9, about 14.9, about 16.6, about 18.1, about 18.3, about 18.8, about 19.5, about 20.1, about 20.9, about 21.6, about 22.4, and about 24.5 degrees 2-theta.
  • the citric acid salt of Compound 1 has at least two characteristic XRPD peaks selected from about 7.3, about 9.0, about 13.6, about 13.9, about 14.9, about 16.6, about 18.1, about 18.3, about 18.8, about 19.5, about 20.1, about 20.9, about 21.6, about 22.4, and about 24.5 degrees 2-theta.
  • the citric acid salt of Compound 1 has at least three characteristic XRPD peaks selected from about 7.3, about 9.0, about 13.6, about 13.9, about 14.9, about 16.6, about 18.1, about 18.3, about 18.8, about 19.5, about 20.1, about 20.9, about 21.6, about 22.4, and about 24.5 degrees 2-theta.
  • the citric acid salt of Compound 1 has an XRPD pattern with characteristic peaks as substantially shown in FIG.22.
  • the citric acid salt of Compound 1 exhibits a DSC thermogram having an endothermic peak at temperatures of about 210 oC.
  • the citric acid salt of Compound 1 has a DSC thermogram substantially as depicted in FIG.23.
  • the citric acid salt of Compound 1 has a TGA thermogram substantially as depicted in FIG.24.
  • the citric acid salt of Compound 1 has at least one characteristic XRPD peak selected from about 7.3, about 9.0, about 13.6, and about 18.3 degrees 2-theta; and the citric acid salt exhibits a DSC thermogram having an endothermic peak at a temperature of about 210 oC.
  • the citric acid salt of Compound 1 is substantially crystalline.
  • the salt is crystalline.
  • Solid Forms of Compound 2 Phosphoric acid salts The phosphoric acid salt of Compound 2 can be prepared by any suitable method for preparation of phosphoric acid addition salts.
  • Compound 2 can be combined with phosphoric acid (e.g., about 1.0 molar eq or more) in a solvent and the resulting salt can be isolated by filtering the salt from solution.
  • Compound 2 is combined with about 1 to about 2 molar equivalents of phosphoric acid.
  • Compound 2 is combined with about 1 to about 1.5 molar equivalents of phosphoric acid.
  • Compound 2 is combined with about 1.05 molar equivalents of phosphoric acid.
  • the solvent is a polar solvent.
  • the solvent is acetone.
  • the phosphoric acid salt of Compound 2 can be crystallized to provide a crystalline solid form.
  • the crystallization of the phosphoric acid salt of Compound 2 comprises precipitating the phosphoric acid salt of Compound 2 from a crystallizing solvent.
  • the crystallizing solvent is acetone.
  • the phosphoric acid salt of Compound 2 has at least one characteristic XRPD peak selected from about 6.7, about 10.2, about 14.5, and about 18.0 degrees 2-theta.
  • the phosphoric acid salt of Compound 2 has at least two characteristic XRPD peaks selected from about 6.7, about 10.2, about 14.5, and about 18.0 degrees 2-theta.
  • the phosphoric acid salt of Compound 2 has at least three characteristic XRPD peaks selected from about 6.7, about 10.2, about 14.5, and about 18.0 degrees 2-theta. In some embodiments, the phosphoric acid salt of Compound 2 has a characteristic XRPD peak at about 6.7 degrees 2-theta. In some embodiments, the phosphoric acid salt of Compound 2 has a characteristic XRPD peak at about 10.2 degrees 2- theta. In some embodiments, the phosphoric acid salt of Compound 2 has a characteristic XRPD peak at about 14.5 degrees 2-theta. In some embodiments, the phosphoric acid salt of Compound 2 has a characteristic XRPD peak at about 18.0 degrees 2-theta.
  • the phosphoric acid salt of Compound 2 has at least one characteristic XRPD peak selected from about 5.9, about 6.7, about 10.2, about 13.4, about 14.5, about 15.5, about 16.5, about 17.4, and about 18.0 degrees 2-theta. In some embodiments, the phosphoric acid salt of Compound 2 has at least two characteristic XRPD peaks selected from about 5.9, about 6.7, about 10.2, about 13.4, about 14.5, about 15.5, about 16.5, about 17.4, and about 18.0 degrees 2-theta. In some embodiments, the phosphoric acid salt of Compound 2 has at least three characteristic XRPD peaks selected from about 5.9, about 6.7, about 10.2, about 13.4, about 14.5, about 15.5, about 16.5, about 17.4, and about 18.0 degrees 2-theta.
  • the phosphoric acid salt of Compound 2 has at least one characteristic XRPD peak selected from about 5.9, about 6.3, about 6.7, about 10.2, about 11.0, about 11.9, about 13.4, about 14.5, about 15.5, about 15.9, about 16.5, about 17.4, about 18.0, about 19.2, about 20.4, and about 23.3 degrees 2-theta.
  • the phosphoric acid salt of Compound 2 has at least two characteristic XRPD peaks selected from about 5.9, about 6.3, about 6.7, about 10.2, about 11.0, about 11.9, about 13.4, about 14.5, about 15.5, about 15.9, about 16.5, about 17.4, about 18.0, about 19.2, about 20.4, and about 23.3 degrees 2-theta.
  • the phosphoric acid salt of Compound 2 has at least three characteristic XRPD peaks selected from about 5.9, about 6.3, about 6.7, about 10.2, about 11.0, about 11.9, about 13.4, about 14.5, about 15.5, about 15.9, about 16.5, about 17.4, about 18.0, about 19.2, about 20.4, and about 23.3 degrees 2-theta.
  • phosphoric acid salt of Compound 2 has an XRPD pattern with characteristic peaks as substantially shown in FIG.25.
  • the phosphoric acid salt of Compound 2 exhibits a DSC thermogram having endothermic peaks at temperatures of about 116 oC and about 200 oC.
  • the phosphoric acid salt of Compound 2 exhibits a DSC thermogram having an endothermic peak at a temperature of about 116 oC. In some embodiments, the phosphoric acid salt of Compound 2 exhibits a DSC thermogram having an endothermic peak at a temperature of about 200 oC. In some embodiments, the phosphoric acid salt of Compound 2 has a DSC thermogram substantially as depicted in FIG.26. In some embodiments, the phosphoric acid salt of Compound 2 has a TGA thermogram substantially as depicted in FIG.27.
  • the phosphoric acid salt of Compound 2 has at least one characteristic XRPD peak selected from about 6.7, about 10.2, about 14.5, and about 18.0 degrees 2-theta; and the phosphoric acid salt of Compound 2 exhibits a DSC thermogram having endothermic peaks at temperatures of about 116 oC and about 200 oC. In some embodiments, the phosphoric acid salt of Compound 2 has at least one characteristic XRPD peak selected from about 6.7, about 10.2, about 14.5, and about 18.0 degrees 2-theta; and the phosphoric acid salt of Compound 2 exhibits a DSC thermogram having an endothermic peak at a temperature of about 116 oC.
  • the phosphoric acid salt of Compound 2 has at least one characteristic XRPD peak selected from about 6.7, about 10.2, about 14.5, and about 18.0 degrees 2-theta; and the phosphoric acid salt of Compound 2 exhibits a DSC thermogram having an endothermic peak at a temperature of about 200 oC.
  • the phosphoric acid salt of Compound 2 is substantially crystalline.
  • the salt is crystalline.
  • the salt is a hydrate.
  • the salt is a dihydrate.
  • Hydrochloric acid salts The hydrochloric acid salt of Compound 2 can be prepared by any suitable method for preparation of hydrochloric acid addition salts.
  • Compound 2 can be combined with hydrochloric acid (e.g., about 1.0 molar eq or more) in a solvent and the resulting salt can be isolated by filtering the salt from solution.
  • hydrochloric acid e.g., about 1.0 molar eq or more
  • Compound 2 is combined with about 1 to about 2 molar equivalents of hydrochloric acid.
  • Compound 2 is combined with about 1 to about 1.5 molar equivalents of hydrochloric acid.
  • Compound 2 is combined with about 1.05 molar equivalents of hydrochloric acid.
  • the solvent is a polar solvent.
  • the solvent is a C1-6 alkyl alcohol.
  • the solvent is methanol.
  • the hydrochloric acid salt of Compound 2 can be crystallized to provide a crystalline solid form.
  • the crystallization of the hydrochloric acid salt of Compound 2 comprises precipitating the hydrochloric acid salt of Compound 1 from a crystallizing solvent.
  • the crystallizing solvent is a polar solvent.
  • the crystallizing solvent is a C1-6 alkyl alcohol.
  • the crystallizing solvent is methanol.
  • the hydrochloric acid salt of Compound 2 has at least one characteristic XRPD peak selected from about 6.2, about 6.8, about 11.2, and about 17.3 degrees 2-theta.
  • the hydrochloric acid salt of Compound 2 has at least two characteristic XRPD peaks selected from about 6.2, about 6.8, about 11.2, and about 17.3 degrees 2-theta. In some embodiments, the hydrochloric acid salt of Compound 2 has at least three characteristic XRPD peaks selected from about 6.2, about 6.8, about 11.2, and about 17.3 degrees 2-theta. In some embodiments, the hydrochloric acid salt of Compound 2 has a characteristic XRPD peak at about 6.2 degrees 2-theta. In some embodiments, the hydrochloric acid salt of Compound 2 has a characteristic XRPD peak at about 6.8 degrees 2- theta.
  • the hydrochloric acid salt of Compound 2 has a characteristic XRPD peak at about 11.2 degrees 2-theta. In some embodiments, the hydrochloric acid salt of Compound 2 has a characteristic XRPD peak at about 17.3 degrees 2-theta. In some embodiments, the hydrochloric acid salt of Compound 2 has at least one characteristic XRPD peak selected from about 6.2, about 6.8, about 11.2, about 12.5, about 13.6, about 17.3, about 18.4, about 21.6, and about 22.3 degrees 2-theta.
  • the hydrochloric acid salt of Compound 2 has at least two characteristic XRPD peaks selected from about 6.2, about 6.8, about 11.2, about 12.5, about 13.6, about 17.3, about 18.4, about 21.6, and about 22.3 degrees 2-theta. In some embodiments, the hydrochloric acid salt of Compound 2 has at least three characteristic XRPD peaks selected from about 6.2, about 6.8, about 11.2, about 12.5, about 13.6, about 17.3, about 18.4, about 21.6, and about 22.3 degrees 2-theta.
  • the hydrochloric acid salt of Compound 2 has at least one characteristic XRPD peak selected from about 6.2, about 6.8, about 11.2, about 12.5, about 13.6, about 13.8, about 16.8, about 17.3, about 18.4, about 21.6, about 22.3, and about 24.1 degrees 2-theta. In some embodiments, the hydrochloric acid salt of Compound 2 has at least two characteristic XRPD peaks selected from about 6.2, about 6.8, about 11.2, about 12.5, about 13.6, about 13.8, about 16.8, about 17.3, about 18.4, about 21.6, about 22.3, and about 24.1 degrees 2-theta.
  • the hydrochloric acid salt of Compound 2 has at least three characteristic XRPD peaks selected from about 6.2, about 6.8, about 11.2, about 12.5, about 13.6, about 13.8, about 16.8, about 17.3, about 18.4, about 21.6, about 22.3, and about 24.1 degrees 2-theta.
  • the hydrochloric salt of Compound 2 has an XRPD pattern with characteristic peaks as substantially shown in FIG.28.
  • the hydrochloric acid salt of Compound 2 exhibits a DSC thermogram having endothermic peaks at temperatures of about 130 oC and about 249 oC.
  • the hydrochloric acid salt of Compound 2 exhibits a DSC thermogram having an endothermic peak at a temperature of about 130 oC. In some embodiments, the hydrochloric acid salt of Compound 2 exhibits a DSC thermogram having an endothermic peak at a temperature of about 249 oC. In some embodiments, the hydrochloric acid salt of Compound 2 has a DSC thermogram substantially as depicted in FIG.29. In some embodiments, the hydrochloric acid salt of Compound 2 has a TGA thermogram substantially as depicted in FIG.30.
  • the hydrochloric acid salt of Compound 2 has at least one characteristic XRPD peak selected from about 6.2, about 6.8, about 11.2, and about 17.3 degrees 2-theta; and the hydrochloric acid salt of Compound 2 exhibits a DSC thermogram having endothermic peaks at temperatures of about 130 oC and about 249 oC. In some embodiments, the hydrochloric acid salt of Compound 2 has at least one characteristic XRPD peak selected from about 6.2, about 6.8, about 11.2, and about 17.3 degrees 2-theta; and the hydrochloric acid salt of Compound 2 exhibits a DSC thermogram having an endothermic peak at a temperature of about 130 oC.
  • the hydrochloric acid salt of Compound 2 has at least one characteristic XRPD peak selected from about 6.2, about 6.8, about 11.2, and about 17.3 degrees 2-theta; and the hydrochloric acid salt of Compound 2 exhibits a DSC thermogram having an endothermic peak at a temperature of about 249 oC.
  • the hydrochloric acid salt of Compound 2 is substantially crystalline. In some embodiments, the salt is crystalline.
  • HPK1 is a negative regulator of T cell and B cell activation (Hu, M.C., et al., Genes Dev, 1996.10(18): p.2251-64; Kiefer, F., et al., EMBO J, 1996.15(24): p.7013-25).
  • HPK1-deficient mouse T cells showed dramatically increased activation of TCR proximal signaling, enhanced IL-2 production, and hyper-proliferation in vitro upon anti-CD3 stimulation (Shui, J.W., et al., Nat Immunol, 2007.8(1): p.84-91).
  • HPK1 knockout B cells produced much higher levels of IgM and IgG isoforms after KLH immunization and displayed hyper-proliferation potentially as a result of enhanced BCR signaling.
  • HPK1 is activated by LCK/ZAP70 (T cells) or SYK/LYN (B cells) mediated-Tyr379 phosphorylation and its subsequent binding to adaptor protein SLP-76 (T cells) or BLNK (B cells) (Wang, X., et al., J Biol Chem, 2012.
  • HPK1-mediated downregulation of these adaptor proteins provide a negative feedback mechanism to attenuate signaling intensity during T cell or B cell activation (Wang, X., et al., J Biol Chem, 2012.287(14): p.11037-48).
  • the bone marrow-derived dendritic cells (BDMCs) from HPK1 knockout mice showed higher expression of co-stimulatory molecules (e.g.
  • HPK1 appears to be a positive regulator of suppressive functions of regulatory T cells (Treg) (Sawasdikosol, S. et al., The journal of immunology, 2012. 188(supplement 1): p.163).
  • HPK1 deficient mouse Foxp3+ Tregs were defective in suppressing TCR-induced effector T cell proliferation, and paradoxically gained the ability to produce IL-2 following TCR engagement (Sawasdikosol, S. et al., The Journal of Immunology, 2012.188(supplement 1): p.163).
  • HPK1 was also involved in PGE2-mediated inhibition of CD4+ T cell activation (Ikegami, R., et al., J Immunol, 2001.166(7): p.4689-96).
  • the proliferation of HPK1 deficient T cells was resistant to the suppressive effects of PGE2 (see US 2007/0087988). Therefore, PGE2-mediated activation of HPK1 may represent a novel regulatory pathway of modulating immune response.
  • the present disclosure provides methods of modulating (e.g., inhibiting) HPK1 activity, by contacting HPK1 with a compound of the invention, or a solid form or salt thereof.
  • the contacting can be administering to a patient a compound provided herein, or a or a solid form or salt thereof.
  • the compounds of the present disclosure, or a solid form or salt thereof are useful for therapeutic administration to enhance, stimulate and/or increase immunity in cancer.
  • a method of treating a disease or disorder associated with inhibition of HPK1 interaction can include administering to a patient in need thereof a therapeutically effective amount of a compound provided herein, or a solid form or salt thereof.
  • the compounds of the present disclosure, or a solid form or salt thereof can be used alone, in combination with other agents or therapies or as an adjuvant or neoadjuvant for the treatment of diseases or disorders, including cancers.
  • any of the compounds of the disclosure, or a solid form or salt thereof, including any of the embodiments thereof, may be used.
  • cancers that are treatable using the compounds of the present disclosure, or solid forms or salts thereof include, but are not limited to, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, testicular cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, endometrial cancer, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, non-Hodgkin's lymphoma, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, chronic or acute leukemias including acute myeloid leukemia, chronic myeloid leukemia
  • cancers treatable with compounds of the present disclosure, or solid forms or salts thereof include melanoma (e.g., metastatic malignant melanoma), renal cancer (e.g. clear cell carcinoma), prostate cancer (e.g. hormone refractory prostate adenocarcinoma), breast cancer, triple-negative breast cancer, colon cancer and lung cancer (e.g. non-small cell lung cancer and small cell lung cancer). Additionally, the disclosure includes refractory or recurrent malignancies whose growth may be inhibited using the compounds of the disclosure, or solid forms or salts thereof.
  • melanoma e.g., metastatic malignant melanoma
  • renal cancer e.g. clear cell carcinoma
  • prostate cancer e.g. hormone refractory prostate adenocarcinoma
  • breast cancer triple-negative breast cancer
  • colon cancer e.g. non-small cell lung cancer and small cell lung cancer
  • lung cancer e.g. non-small cell lung cancer and small cell lung cancer
  • diseases and indications that are treatable using the compounds of the present disclosure, or solid forms or salts thereof include but are not limited to hematological cancers, sarcomas, lung cancers, gastrointestinal cancers, genitourinary tract cancers, liver cancers, bone cancers, nervous system cancers, gynecological cancers, and skin cancers.
  • Exemplary hematological cancers include lymphomas and leukemias such as acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), acute promyelocytic leukemia (APL), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma, Non-Hodgkin lymphoma (including relapsed or refractory NHL and recurrent follicular), Hodgkin lymphoma, myeloproliferative diseases (e.g., primary myelofibrosis (PMF), polycythemia vera (PV), essential thrombocytosis (ET)), myelodysplasia syndrome (MDS), T-cell acute lymphoblastic lymphoma (T-ALL), multiple myeloma, cutaneous T-cell lymphoma, Waldenstrom's Macroglubulinemia,
  • Exemplary sarcomas include chondrosarcoma, Ewing’s sarcoma, osteosarcoma, rhabdomyosarcoma, angiosarcoma, fibrosarcoma, liposarcoma, myxoma, rhabdomyoma, rhabdosarcoma, fibroma, lipoma, harmatoma, and teratoma.
  • Exemplary lung cancers include non-small cell lung cancer (NSCLC), small cell lung cancer, bronchogenic carcinoma (squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, chondromatous hamartoma, and mesothelioma.
  • NSCLC non-small cell lung cancer
  • small cell lung cancer bronchogenic carcinoma
  • squamous cell undifferentiated small cell, undifferentiated large cell
  • adenocarcinoma adenocarcinoma
  • alveolar (bronchiolar) carcinoma bronchial adenoma
  • chondromatous hamartoma chondromatous hamartoma
  • mesothelioma mesothelioma
  • Exemplary gastrointestinal cancers include cancers of the esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small bowel (adenocarcinoma, lymphoma, carcinoid tumors, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large bowel (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma), and colorectal cancer.
  • esophagus squamous cell carcinoma, adenocarcinoma, leiomy
  • Exemplary genitourinary tract cancers include cancers of the kidney (adenocarcinoma, Wilm's tumor [nephroblastoma]), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), and testis (seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma).
  • Exemplary liver cancers include hepatoma (hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, and hemangioma.
  • Exemplary bone cancers include, for example, osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochronfroma (osteocartilaginous exostoses), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma, and giant cell tumors
  • Exemplary nervous system cancers include cancers of the skull (osteoma, hemangioma, granuloma,
  • Exemplary gynecological cancers include cancers of the uterus (endometrial carcinoma), cervix (cervical carcinoma, pre -tumor cervical dysplasia), ovaries (ovarian carcinoma (serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma), granulosa-thecal cell tumors, Sertoli-Leydig cell tumors, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma), and fallopian tubes (carcinoma).
  • endometrial carcinoma endometrial carcinoma
  • cervix cervical carcinoma, pre -tumor cervical dysplasia
  • Exemplary skin cancers include melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, Merkel cell skin cancer, moles dysplastic nevi, lipoma, angioma, dermatofibroma, and keloids.
  • diseases and indications that are treatable using the compounds of the present disclosure include, but are not limited to, sickle cell disease (e.g., sickle cell anemia), triple-negative breast cancer (TNBC), myelodysplastic syndromes, testicular cancer, bile duct cancer, esophageal cancer, and urothelial carcinoma.
  • Exemplary head and neck cancers include glioblastoma, melanoma, rhabdosarcoma, lymphosarcoma, osteosarcoma, squamous cell carcinomas, adenocarcinomas, oral cancer, laryngeal cancer, nasopharyngeal cancer, nasal and paranasal cancers, thyroid and parathyroid cancers.
  • HPK1 inhibitors may be used to treat tumors producing PGE2 (e.g. Cox-2 overexpressing tumors) and/or adenosine (CD73 and CD39 over-expressing tumors).
  • Cox-2 has been detected in a number of tumors, such as colorectal, breast, pancreatic and lung cancers, where it correlates with a poor prognosis.
  • Overexpression of COX-2 has been reported in hematological cancer models such as RAJI (Burkitt’s lymphoma) and U937 (acute promonocytic leukemia) as well as in patient’s blast cells.
  • CD73 is up-regulated in various human carcinomas including those of colon, lung, pancreas and ovary. Importantly, higher expression levels of CD73 are associated with tumor neovascularization, invasiveness, and metastasis and with shorter patient survival time in breast cancer.
  • the term “contacting” refers to the bringing together of the indicated moieties in an in vitro system or an in vivo system such that they are in sufficient physical proximity to interact.
  • the terms "individual” or “patient,” used interchangeably, refer to any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates, and most preferably humans.
  • the phrase "therapeutically effective amount” refers to the amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue, system, animal, individual or human that is being sought by a researcher, veterinarian, medical doctor or other clinician.
  • treating refers to one or more of (1) inhibiting the disease; e.g., inhibiting a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., arresting further development of the pathology and/or symptomatology); and (2) ameliorating the disease; e.g., ameliorating a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., reversing the pathology and/or symptomatology) such as decreasing the severity of disease.
  • the compounds of the invention, or solid forms or salts thereof are useful in preventing or reducing the risk of developing any of the diseases referred to herein; e.g., preventing or reducing the risk of developing a disease, condition or disorder in an individual who may be predisposed to the disease, condition or disorder but does not yet experience or display the pathology or symptomatology of the disease.
  • Combination Therapies I. Immune-checkpoint therapies In some embodiments, the compounds provided herein, or solid forms or salts thereof, can be used in combination with one or more immune checkpoint inhibitors for the treatment of cancer as described herein. Compounds of the present disclosure, or solid forms or salts thereof, can be used in combination with one or more immune checkpoint inhibitors.
  • immune checkpoint inhibitors include inhibitors against immune checkpoint molecules such as CD20, CD28, CD39, CD40, CD122, CD96, CD73, CD47, GITR, CSF1R, JAK, PI3K delta, PI3K gamma, TAM, arginase, CD137 (also known as 4-1BB), ICOS, B7- H3, B7-H4, BTLA, CTLA-4, LAG3, TIM3, VISTA, TIGIT, PD-1, PD-L1 and PD-L2.
  • the immune checkpoint molecule is a stimulatory checkpoint molecule selected from CD27, CD28, CD40, ICOS, OX40, GITR and CD137.
  • the immune checkpoint molecule is an inhibitory checkpoint molecule selected from A2AR, B7-H3, B7-H4, BTLA, CTLA-4, IDO, KIR, LAG3, PD-1, TIM3, TIGIT, and VISTA.
  • the compounds of the disclosure provided herein, or solid forms or salts thereof can be used in combination with one or more agents selected from KIR inhibitors, TIGIT inhibitors, LAIR1 inhibitors, CD160 inhibitors, 2B4 inhibitors and TGFR beta inhibitors.
  • the compounds provided herein, or solid forms or salts thereof can be used in combination with one or more agonists of immune checkpoint molecules, e.g., OX40, CD27, GITR, and CD137 (also known as 4-1BB).
  • the inhibitor of an immune checkpoint molecule is anti-PD1 antibody, anti-PD-L1 antibody, or anti-CTLA-4 antibody.
  • the inhibitor of an immune checkpoint molecule is an inhibitor of PD-1, e.g., an anti-PD-1 monoclonal antibody.
  • the anti-PD-1 monoclonal antibody is nivolumab, pembrolizumab (also known as MK-3475), durvalumab (Imfinzi®), pidilizumab, SHR-1210, PDR001, MGA012, PDR001, AB122, or AMP-224.
  • the anti-PD-1 monoclonal antibody is nivolumab or pembrolizumab.
  • the anti-PD1 antibody is pembrolizumab.
  • the anti-PD-1 monoclonal antibody is MGA012.
  • the anti-PD1 antibody is SHR-1210.
  • anti-cancer agent(s) include antibody therapeutics such as 4-1BB (e.g. urelumab, utomilumab).
  • the inhibitor of an immune checkpoint molecule is an inhibitor of PD-L1, e.g., an anti-PD-L1 monoclonal antibody.
  • the anti-PD-L1 monoclonal antibody is BMS-935559, MEDI4736, MPDL3280A (also known as RG7446), or MSB0010718C.
  • the anti-PD-L1 monoclonal antibody is MPDL3280A or MEDI4736.
  • the inhibitor of an immune checkpoint molecule is an inhibitor of PD-1 and PD-L1, e.g., an anti-PD-1/PD-L1 monoclonal antibody.
  • the anti-PD-1/PD-L1 is MCLA-136.
  • the inhibitor is MCLA-145.
  • the inhibitor of an immune checkpoint molecule is an inhibitor of CTLA-4, e.g., an anti-CTLA-4 antibody.
  • the anti-CTLA-4 antibody is ipilimumab, tremelimumab, AGEN1884, or CP-675,206.
  • the inhibitor of an immune checkpoint molecule is an inhibitor of CSF1R, e.g., an anti- CSF1R antibody.
  • the anti- CSF1R antibody is IMC-CS4 or RG7155.
  • the inhibitor of an immune checkpoint molecule is an inhibitor of LAG3, e.g., an anti-LAG3 antibody.
  • the anti-LAG3 antibody is BMS-986016, LAG525, IMP321, GSK2831781, or INCAGN2385.
  • the inhibitor of an immune checkpoint molecule is an inhibitor of TIM3, e.g., an anti-TIM3 antibody.
  • the anti-TIM3 antibody is INCAGN2390, MBG453, or TSR-022.
  • the inhibitor of an immune checkpoint molecule is an inhibitor of GITR, e.g., an anti-GITR antibody.
  • the anti-GITR antibody is TRX518, MK-4166, INCAGN1876, MK-1248, AMG228, BMS-986156, GWN323, or MEDI1873.
  • the inhibitor of an immune checkpoint molecule is an agonist of OX40, e.g., OX40 agonist antibody or OX40L fusion protein.
  • the anti-OX40 antibody is INCAGN01949, MEDI0562, MEDI6469, MOXR-0916, PF- 04518600, GSK3174998, or BMS-986178.
  • the OX40L fusion protein is MEDI6383.
  • the inhibitor of an immune checkpoint molecule is an inhibitor of CD20, e.g., an anti-CD20 antibody.
  • the anti-CD20 antibody is obinutuzumab or rituximab.
  • the compounds of the present disclosure, or solid forms or salts thereof, can be used in combination with bispecific antibodies.
  • one of the domains of the bispecific antibody targets PD-1, PD-L1, CTLA-4, GITR, OX40, TIM3, LAG3, CD137, ICOS, CD3 or TGFb receptor.
  • the compounds of the disclosure, or solid forms or salts thereof can be used in combination with one or more metabolic enzyme inhibitors.
  • the metabolic enzyme inhibitor is an inhibitor of IDO1, TDO, or arginase.
  • IDO1 inhibitors include epacadostat, NLG919, BMS-986205, PF-06840003, IOM2983, RG-70099 and LY338196.
  • An example of an arginase inhibitor is CB-1158.
  • the additional compounds, inhibitors, agents, etc. can be combined with the present compound in a single or continuous dosage form, or they can be administered simultaneously or sequentially as separate dosage forms.
  • Cancer therapies Cancer cell growth and survival can be impacted by multiple signaling pathways. Thus, it is useful to combine different enzyme/protein/receptor inhibitors, exhibiting different preferences in the targets which they modulate the activities of, to treat such conditions.
  • agents that may be combined with compounds of the present disclosure, or solid forms or salts thereof, include inhibitors of the PI3K-AKT-mTOR pathway, inhibitors of the Raf-MAPK pathway, inhibitors of JAK-STAT pathway, inhibitors of beta catenin pathway, inhibitors of notch pathway, inhibitors of hedgehog pathway, inhibitors of Pim kinases, and inhibitors of protein chaperones and cell cycle progression.
  • Targeting more than one signaling pathway may reduce the likelihood of drug-resistance arising in a cell population, and/or reduce the toxicity of treatment.
  • the compounds of the present disclosure, or solid forms or salts thereof can be used in combination with one or more other enzyme/protein/receptor inhibitors for the treatment of diseases, such as cancer.
  • cancers include solid tumors and liquid tumors, such as blood cancers.
  • the compounds of the present disclosure, or solid forms or salts thereof can be combined with one or more inhibitors of the following kinases for the treatment of cancer: Akt1, Akt2, Akt3, TGF-bR, PKA, PKG, PKC, CaM-kinase, phosphorylase kinase, MEKK, ERK, MAPK, mTOR, EGFR, HER2, HER3, HER4, INS-R, IGF-1R, IR-R, PDGFaR, PDGFbR, CSFIR, KIT, FLK-II, KDR/FLK-1, FLK-4, flt-1, FGFR1, FGFR2, FGFR3, FGFR4, c-Met, Ron, Sea, TR
  • the compounds of the present disclosure, or solid forms or salts thereof can be combined with one or more of the following inhibitors for the treatment of cancer.
  • inhibitors that can be combined with the compounds of the present disclosure, or solid forms or salts thereof, for treatment of cancers include an FGFR inhibitor (FGFR1, FGFR2, FGFR3 or FGFR4, e.g., AZD4547, BAY1187982, ARQ087, BGJ398, BIBF1120, TKI258, lucitanib, dovitinib, TAS- 120, JNJ-42756493, Debio1347, INCB54828, INCB62079 and INCB63904), a JAK inhibitor (JAK1 and/or JAK2, e.g., ruxolitinib, baricitinib or INCB39110), an IDO inhibitor (e.g., epacadostat and NLG919), an LSD1 inhibitor (e.g., GSK29), e.g., G
  • Inhibitors of HDAC such as panobinostat and vorinostat.
  • Inhibitors of c-Met such as onartumzumab, tivantnib, and INC-280.
  • Inhibitors of BTK such as ibrutinib.
  • Inhibitors of mTOR such as rapamycin, sirolimus, temsirolimus, and everolimus.
  • Inhibitors of Raf such as vemurafenib and dabrafenib.
  • Inhibitors of MEK such as trametinib, selumetinib and GDC-0973.
  • Hsp90 e.g., tanespimycin
  • cyclin dependent kinases e.g., palbociclib
  • PARP e.g., olaparib
  • Pim kinases LGH447, INCB053914 and SGI-1776
  • the agent is an alkylating agent, a proteasome inhibitor, a corticosteroid, or an immunomodulatory agent.
  • alkylating agent examples include bendamustine, nitrogen mustards, ethylenimine derivatives, alkyl sulfonates, nitrosoureas and triazenes, uracil mustard, chlormethine, cyclophosphamide (CytoxanTM), ifosfamide, melphalan, chlorambucil, pipobroman, triethylene-melamine, triethylenethiophosphoramine, busulfan, carmustine, lomustine, streptozocin, dacarbazine, and temozolomide.
  • the proteasome inhibitor is carfilzomib.
  • the corticosteroid is dexamethasone (DEX).
  • the immunomodulatory agent is lenalidomide (LEN) or pomalidomide (POM).
  • LN lenalidomide
  • POM pomalidomide
  • the compounds of the present disclosure, or solid forms or salts thereof, can further be used in combination with other methods of treating cancers, for example by chemotherapy, irradiation therapy, tumor-targeted therapy, adjuvant therapy, immunotherapy or surgery.
  • immunotherapy examples include cytokine treatment (e.g., interferons, GM- CSF, G-CSF, IL-2), CRS-207 immunotherapy, cancer vaccine, monoclonal antibody, adoptive T cell transfer, CAR (Chimeric antigen receptor) T cell treatment as a booster for T cell activation, oncolytic virotherapy and immunomodulating small molecules, including thalidomide or JAK1/2 inhibitor and the like.
  • cytokine treatment e.g., interferons, GM- CSF, G-CSF, IL-2
  • CRS-207 immunotherapy cancer vaccine
  • monoclonal antibody adoptive T cell transfer
  • CAR Chimeric antigen receptor
  • T cell treatment as a booster for T cell activation
  • oncolytic virotherapy examples include immunomodulating small molecules, including thalidomide or JAK1/2 inhibitor and the like.
  • the compounds can be administered in combination with one or more anti-cancer drugs, such as a chemotherapeutics.
  • Example chemotherapeutics include any of: abarelix, abiraterone, afatinib, aflibercept, aldesleukin, alemtuzumab, alitretinoin, allopurinol, altretamine, amsacrine, anastrozole, aphidicolon, arsenic trioxide, asparaginase, axitinib, azacitidine, bevacizumab, bexarotene, baricitinib, bicalutamide, bleomycin, bortezombi, bortezomib, brivanib, buparlisib, busulfan intravenous, busulfan oral, calusterone, camptosar, capecitabine, carboplatin, carmustine, cediranib, cetuximab, chlorambucil, cisplatin, cladribine, clofarabine, crizotinib,
  • anti-cancer agent(s) include antibody therapeutics such as trastuzumab (Herceptin), antibodies to costimulatory molecules such as CTLA-4 (e.g., ipilimumab or tremelimumab), 4-1BB, antibodies to PD-1 and PD-L1, or antibodies to cytokines (IL-10, TGF-b, etc.).
  • CTLA-4 e.g., ipilimumab or tremelimumab
  • 4-1BB antibodies to PD-1 and PD-L1
  • antibodies to cytokines IL-10, TGF-b, etc.
  • Examples of antibodies to PD-1 and/or PD-L1 that can be combined with compounds of the present disclosure for the treatment of cancer or infections such as viral, bacteria, fungus and parasite infections include, but are not limited to, nivolumab, pembrolizumab, MPDL3280A, MEDI-4736 and SHR-1210.
  • anti-cancer agents include inhibitors of kinases associated cell proliferative disorder. These kinases include but not limited to Aurora-A, CDK1, CDK2, CDK3, CDK5, CDK7, CDK8, CDK9, ephrin receptor kinases, CHK1, CHK2, SRC, Yes, Fyn, Lck, Fer, Fes, Syk, Itk, Bmx, GSK3, JNK, PAK1, PAK2, PAK3, PAK4, PDK1, PKA, PKC, Rsk and SGK. Other anti-cancer agents also include those that block immune cell migration such as antagonists to chemokine receptors, including CCR2 and CCR4.
  • the compounds of the present disclosure, or solid forms or salts thereof, can further be used in combination with one or more anti-inflammatory agents, steroids, immunosuppressants or therapeutic antibodies.
  • the steroids include but are not limited to 17 alpha-ethinylestradiol, diethylstilbestrol, testosterone, prednisone, fluoxymesterone, methylprednisolone, methyltestosterone, prednisolone, triamcinolone, chlorotrianisene, hydroxyprogesterone, aminoglutethimide, and medroxyprogesteroneacetate.
  • the compounds of the present disclosure, or solid forms or salts thereof can also be used in combination with lonafarnib (SCH6636), tipifarnib (R115777), L778123, BMS 214662, tezacitabine (MDL 101731), Sml1, triapine, didox, trimidox and amidox.
  • the compounds of the disclosure, or salts or solid forms thereof can be combined with another immunogenic agent, such as cancerous cells, purified tumor antigens (including recombinant proteins, peptides, and carbohydrate molecules), cells, and cells transfected with genes encoding immune stimulating cytokines.
  • Non-limiting examples of tumor vaccines that can be used include peptides of melanoma antigens, such as peptides of gp100, MAGE antigens, Trp-2, MARTI and/or tyrosinase, or tumor cells transfected to express the cytokine GM-CSF.
  • the compounds of the present disclosure, or solid forms or salts thereof, can be used in combination with a vaccination protocol for the treatment of cancer.
  • the tumor cells are transduced to express GM-CSF.
  • tumor vaccines include the proteins from viruses implicated in human cancers such as Human Papilloma Viruses (HPV), Hepatitis Viruses (HBV and HCV) and Kaposi's Herpes Sarcoma Virus (KHSV).
  • HPV Human Papilloma Viruses
  • HBV and HCV Hepatitis Viruses
  • KHSV Kaposi's Herpes Sarcoma Virus
  • the compounds of the present disclosure, or solid forms or salts thereof can be used in combination with tumor specific antigen such as heat shock proteins isolated from tumor tissue itself.
  • the compounds of the present disclosure, or solid forms or salts thereof can be combined with dendritic cells immunization to activate potent anti-tumor responses.
  • the compounds of the present disclosure, or solid forms or salts thereof can be used in combination with bispecific macrocyclic peptides that target Fe alpha or Fe gamma receptor-expressing effectors cells to tumor cells.
  • the compounds of the present disclosure, or solid forms or salts thereof can also be combined with macrocyclic peptides that activate host immune responsiveness.
  • the compounds of the present disclosure, or solid forms or salts thereof can be used in combination with bone marrow transplant for the treatment of a variety of tumors of hematopoietic origin.
  • Suitable antiviral agents contemplated for use in combination with the compounds of the present disclosure can comprise nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors and other antiviral drugs.
  • NRTIs nucleoside and nucleotide reverse transcriptase inhibitors
  • NRTIs non-nucleoside reverse transcriptase inhibitors
  • protease inhibitors and other antiviral drugs.
  • Example suitable NRTIs include zidovudine (AZT); didanosine (ddl); zalcitabine (ddC); stavudine (d4T); lamivudine (3TC); abacavir (1592U89); adefovir dipivoxil [bis(POM)-PMEA]; lobucavir (BMS-180194); BCH-10652; emitricitabine [(-)-FTC]; beta-L- FD4 (also called beta-L-D4C and named beta-L-2', 3'-dicleoxy-5-fluoro-cytidene); DAPD, ((-)-beta-D-2,6,-diamino-purine dioxolane); and lodenosine (FddA).
  • ZT zidovudine
  • ddl didanosine
  • ddC zalcitabine
  • stavudine d4T
  • NNRTIs include nevirapine (BI-RG-587); delaviradine (BHAP, U-90152); efavirenz (DMP- 266); PNU-142721; AG-1549; MKC-442 (1-(ethoxy-methyl)-5-(1-methylethyl)-6- (phenylmethyl)-(2,4(1H,3H)-pyrimidinedione); and (+)-calanolide A (NSC-675451) and B.
  • Typical suitable protease inhibitors include saquinavir (Ro 31-8959); ritonavir (ABT-538); indinavir (MK-639); nelfnavir (AG-1343); amprenavir (141W94); lasinavir (BMS-234475); DMP-450; BMS-2322623; ABT-378; and AG-1549.
  • Other antiviral agents include hydroxyurea, ribavirin, IL-2, IL-12, pentafuside and Yissum Project No.11607.
  • the compounds of the present disclosure, or solid forms or salts thereof can be used in combination with INCB086550.
  • Formulation, Dosage Forms and Administration When employed as pharmaceuticals, the compounds of the present disclosure, or solid forms or salts thereof, can be administered in the form of pharmaceutical compositions.
  • the present disclosure provides a composition comprising the compounds of the present disclosure, or solid forms or salts thereof, and at least one pharmaceutically acceptable carrier or excipient.
  • These compositions can be prepared in a manner well known in the pharmaceutical art, and can be administered by a variety of routes, depending upon whether local or systemic treatment is indicated and upon the area to be treated.
  • Administration may be topical (including transdermal, epidermal, ophthalmic and to mucous membranes including intranasal, vaginal and rectal delivery), pulmonary (e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal or intranasal), oral or parenteral.
  • Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal intramuscular or injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration.
  • Parenteral administration can be in the form of a single bolus dose, or may be, e.g., by a continuous perfusion pump.
  • compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders.
  • Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.
  • This invention also includes pharmaceutical compositions which contain, as the active ingredient the compounds of the present disclosure, or solid forms or salts thereof, in combination with one or more pharmaceutically acceptable carriers or excipients.
  • the composition is suitable for topical administration.
  • the active ingredient is typically mixed with an excipient, diluted by an excipient or enclosed within such a carrier in the form of, e.g., a capsule, sachet, paper, or other container.
  • a carrier in the form of, e.g., a capsule, sachet, paper, or other container.
  • the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient.
  • compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, e.g., up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions and sterile packaged powders.
  • the active compound can be milled to provide the appropriate particle size prior to combining with the other ingredients. If the active compound is substantially insoluble, it can be milled to a particle size of less than 200 mesh.
  • the particle size can be adjusted by milling to provide a substantially uniform distribution in the formulation, e.g., about 40 mesh.
  • the compounds of the present disclosure, or solid forms or salts thereof, may be milled using known milling procedures such as wet milling to obtain a particle size appropriate for tablet formation and for other formulation types.
  • Finely divided (nanoparticulate) preparations of the compounds of the invention can be prepared by processes known in the art see, e.g., WO 2002/000196.
  • excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup and methyl cellulose.
  • the formulations can additionally include: lubricating agents such as talc, magnesium stearate and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxy-benzoates; sweetening agents; and flavoring agents.
  • compositions of the invention can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.
  • the pharmaceutical composition comprises silicified microcrystalline cellulose (SMCC) and at least one compound described herein, or a pharmaceutically acceptable salt thereof.
  • the silicified microcrystalline cellulose comprises about 98% microcrystalline cellulose and about 2% silicon dioxide w/w.
  • the composition is a sustained release composition comprising a compound of the present disclosure, or a solid form or salt thereof, and at least one pharmaceutically acceptable carrier or excipient.
  • the composition comprises at least one compound described herein, or a pharmaceutically acceptable salt thereof, and at least one component selected from microcrystalline cellulose, lactose monohydrate, hydroxypropyl methylcellulose and polyethylene oxide. In some embodiments, the composition comprises at least one compound described herein, or a pharmaceutically acceptable salt thereof, and microcrystalline cellulose, lactose monohydrate and hydroxypropyl methylcellulose. In some embodiments, the composition comprises at least one compound described herein, or a pharmaceutically acceptable salt thereof, and microcrystalline cellulose, lactose monohydrate and polyethylene oxide. In some embodiments, the composition further comprises magnesium stearate or silicon dioxide. In some embodiments, the microcrystalline cellulose is Avicel PH102TM.
  • the lactose monohydrate is Fast-flo 316TM.
  • the hydroxypropyl methylcellulose is hydroxypropyl methylcellulose 2208 K4M (e.g., Methocel K4 M PremierTM) and/or hydroxypropyl methylcellulose 2208 K100LV (e.g., Methocel K00LVTM).
  • the polyethylene oxide is polyethylene oxide WSR 1105 (e.g., Polyox WSR 1105TM).
  • a wet granulation process is used to produce the composition.
  • a dry granulation process is used to produce the composition.
  • compositions can be formulated in a unit dosage form, each dosage containing from about 5 to about 1,000 mg (1 g), more usually about 100 mg to about 500 mg, of the active ingredient. In some embodiments, each dosage contains about 10 mg of the active ingredient. In some embodiments, each dosage contains about 50 mg of the active ingredient. In some embodiments, each dosage contains about 25 mg of the active ingredient.
  • unit dosage forms refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.
  • the components used to formulate the pharmaceutical compositions are of high purity and are substantially free of potentially harmful contaminants (e.g., at least National Food grade, generally at least analytical grade, and more typically at least pharmaceutical grade).
  • the composition is preferably manufactured or formulated under Good Manufacturing Practice standards as defined in the applicable regulations of the U.S. Food and Drug Administration.
  • suitable formulations may be sterile and/or substantially isotonic and/or in full compliance with all Good Manufacturing Practice regulations of the U.S. Food and Drug Administration.
  • the active compound may be effective over a wide dosage range and is generally administered in a therapeutically effective amount.
  • the amount of the compound actually administered will usually be determined by a physician, according to the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms and the like.
  • the therapeutic dosage of a compound of the present invention, or a solid form or salt thereof can vary according to, e.g., the particular use for which the treatment is made, the manner of administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician.
  • the proportion or concentration of a compound of the disclosure in a pharmaceutical composition can vary depending upon a number of factors including dosage, chemical characteristics (e.g., hydrophobicity), and the route of administration.
  • the compounds of the invention or a salt or solid form thereof can be provided in an aqueous physiological buffer solution containing about 0.1 to about 10% w/v of the compound for parenteral administration.
  • Some typical dose ranges are from about 1 g/kg to about 1 g/kg of body weight per day. In some embodiments, the dose range is from about 0.01 mg/kg to about 100 mg/kg of body weight per day.
  • the dosage is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, formulation of the excipient, and its route of administration. Effective doses can be extrapolated from dose-response curves derived from in vitro or animal model test systems.
  • the principal active ingredient is mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention.
  • a solid preformulation composition containing a homogeneous mixture of a compound of the present invention.
  • the active ingredient is typically dispersed evenly throughout the composition so that the composition can be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules.
  • This solid preformulation is then subdivided into unit dosage forms of the type described above containing from, e.g., about 0.1 to about 1000 mg of the active ingredient of the present invention.
  • the tablets or pills of the present invention can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action.
  • the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former.
  • the two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release.
  • enteric layers or coatings such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.
  • compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders.
  • the liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra.
  • the compositions are administered by the oral or nasal respiratory route for local or systemic effect.
  • compositions can be nebulized by use of inert gases. Nebulized solutions may be breathed directly from the nebulizing device or the nebulizing device can be attached to a face mask, tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions can be administered orally or nasally from devices which deliver the formulation in an appropriate manner.
  • Topical formulations can contain one or more conventional carriers.
  • ointments can contain water and one or more hydrophobic carriers selected from, e.g., liquid paraffin, polyoxyethylene alkyl ether, propylene glycol, white Vaseline, and the like.
  • Carrier compositions of creams can be based on water in combination with glycerol and one or more other components, e.g., glycerinemonostearate, PEG-glycerinemonostearate and cetylstearyl alcohol.
  • Gels can be formulated using isopropyl alcohol and water, suitably in combination with other components such as, e.g., glycerol, hydroxyethyl cellulose, and the like.
  • topical formulations contain at least about 0.1, at least about 0.25, at least about 0.5, at least about 1, at least about 2 or at least about 5 wt % of the compound of the invention.
  • the topical formulations can be suitably packaged in tubes of, e.g., 100 g which are optionally associated with instructions for the treatment of the select indication, e.g., psoriasis or other skin condition.
  • the amount of compound or composition administered to a patient will vary depending upon what is being administered, the purpose of the administration, such as prophylaxis or therapy, the state of the patient, the manner of administration and the like.
  • compositions can be administered to a patient already suffering from a disease in an amount sufficient to cure or at least partially arrest the symptoms of the disease and its complications. Effective doses will depend on the disease condition being treated as well as by the judgment of the attending clinician depending upon factors such as the severity of the disease, the age, weight and general condition of the patient and the like.
  • compositions administered to a patient can be in the form of pharmaceutical compositions described above. These compositions can be sterilized by conventional sterilization techniques, or may be sterile filtered. Aqueous solutions can be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration.
  • the pH of the compound preparations typically will be between 3 and 11, more preferably from 5 to 9 and most preferably from 7 to 8. It will be understood that use of certain of the foregoing excipients, carriers or stabilizers will result in the formation of pharmaceutical salts.
  • the therapeutic dosage of a compound of the present invention, or a solid form or salt thereof can vary according to, e.g., the particular use for which the treatment is made, the manner of administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician.
  • the proportion or concentration of a compound of the invention, or a solid form or salt thereof, in a pharmaceutical composition can vary depending upon a number of factors including dosage, chemical characteristics (e.g., hydrophobicity), and the route of administration.
  • the compounds of the invention, or solid forms or salts thereof can be provided in an aqueous physiological buffer solution containing about 0.1 to about 10% w/v of the compound for parenteral administration.
  • Some typical dose ranges are from about 1 ⁇ g/kg to about 1 g/kg of body weight per day. In some embodiments, the dose range is from about 0.01 mg/kg to about 100 mg/kg of body weight per day.
  • the dosage is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, formulation of the excipient, and its route of administration. Effective doses can be extrapolated from dose- response curves derived from in vitro or animal model test systems.
  • XRPD Bruker D8 Advance ECO X-ray Powder Diffractometer
  • the general experimental procedures for XRPD were: (1) X-ray radiation from copper at 1.5418 ⁇ and LYNXEYE TM detector; (2) X-ray power at 40 kV, 25 mA; and (3) the sample powder was dispersed on a zero-background sample holder.
  • the general measurement conditions for XRPD were: Start Angle 3 degrees; Stop Angle 30 degrees; Sampling 0.015 degrees; and Scan speed 2 degree/min.
  • Differential Scanning Calorimetry (DSC) was carried out on a TA Instruments Differential Scanning Calorimetry, Discovery DSC2500 with autosampler.
  • the DSC instrument conditions were as follows: 20-300 ⁇ C at 10 ⁇ C/min; Tzero aluminum sample pan and lid; and nitrogen gas flow at 50 mL/min.
  • Thermogravimetric analysis (TGA) was carried out on a TA Instruments Thermogravimetric Analyzer, Discovery TGA5500 with autosampler.
  • the general experimental conditions for TGA were: ramp from 25 ⁇ C to 300 ⁇ C at 10 ⁇ C/min; nitrogen purge gas flow at 25 mL/min; platinum sample holder.
  • Example 1 Preparation of Compound 1 Step 1.
  • Example 2 Preparation of Compound 2 Step 1. tert-Butyl ((3S,5S)-1-(5-bromo-2-nitrophenyl)-5-(hydroxymethyl)pyrrolidin-3- yl)carbamate A solution of 4-bromo-2-fluoro-1-nitrobenzene (532 mg, 2.42 mmol) and tert-butyl ((3S,5S)-5-(hydroxymethyl)pyrrolidin-3-yl)carbamate (523 mg, 2.42 mmol) in DMSO (8 mL) was treated with triethylamine (506 ⁇ L, 3.63 mmol) and the reaction mixture was heated to 80 °C for 2 hr.
  • Example 3 Synthesis of crystalline Form I of Compound 1 Form I of Compound 1 was obtained by stirring 52.63 mg of the amorphous free base in 1 mL of isopropyl alcohol (IPA) in a 4 mL clear glass vial at room temperature overnight. The crystalline solid was collected by filtration and air dried. Form I was confirmed as a crystalline solid according to XRPD analysis. The XRPD pattern of Form I is shown in FIG.1 and the peak data is given below in Table 1. Table 1. XRPD Peak Data for Free Base Form I.
  • IPA isopropyl alcohol
  • DSC analysis of the free base Form I revealed a first endothermic peak with an onset temperature of 57.3 °C and a maximum at 86.2 °C and a second endothermic peak with an onset temperature of 182.8 °C and a maximum at 183.4 °C
  • the DSC thermogram is provided in FIG.2.
  • TGA analysis of the free base Form I revealed 10.4% weight loss below 100 °C and significant weight loss above 200 °C due to decomposition of the sample.
  • the TGA thermogram is provided in FIG.3.
  • Example 4 Preparation and Characterization of Compound 1 Phosphate Salt 104.5 mg of Compound 1 was added in 1 mL of methanol in a 4 mL clear glass vial with stirring.
  • DSC analysis of phosphate salt revealed a first endothermic peak with an onset temperature of 56.6 °C and a maximum at 92.5 °C and a second endothermic peak with an onset temperature of 220.3 °C and a maximum at 228.9 °C.
  • the DSC thermogram is provided in FIG. 5.
  • TGA analysis of the phosphate salt revealed 18.7% weight loss below 100 °C and significant weight loss above 200 °C due to decomposition of the sample.
  • the TGA thermogram is provided in FIG.6.
  • Example 5 Preparation and Characterization of Compound 1 hydrochloride Salt 112.4 mg of Compound 1 was combined with 1 mL of methanol in a 4 mL clear glass vial with stirring.
  • DSC analysis of the hydrochloride salt revealed a first endothermic peak with an onset temperature of 106.3 °C and a maximum at 107.2 °C and a second endothermic peak with an onset temperature of 230.9 °C and a maximum at 232.7 °C. An exothermic peak was also observed around 160-175 °C.
  • the DSC thermogram is provided in FIG.8.
  • TGA analysis of the hydrochloride salt revealed 11.2% weight loss below 125 °C and significant weight loss above 225 °C due to decomposition of the sample.
  • the TGA thermogram is provided in FIG.9.
  • Example 6 Preparation and Characterization of Compound 1 L-Tartrate Salt 98.9 mg of Compound 1 was combined with 2 mL of methanol in a 4 mL clear glass vial with stirring. To the solution/suspension, 37.53 mg of L-tartaric acid (1.15 eq) was added and mixed well. Solid precipitated quickly. The resultant suspension was stirred for 1 h at room temperature. The solid L-tartrate salt was collected by filtration and air dried. The dried solid was treated with 2 mL of water in a 4 mL clear glass vial and stirred overnight at room temperature. The recrystallized solid of the L-tartrate salt was collected by filtration and dried at 30 °C under vacuum overnight.
  • the salt ratio between the free base and L-tartaric acid was determined to be 1.0 by NMR analysis.
  • the L-tartrate salt was confirmed as a crystalline solid according to XRPD analysis.
  • the XRPD pattern of the L-tartrate salt is shown in FIG.10 and the peak data is given below in Table 4.
  • Table 4. XRPD Peak Data for L-Tartrate Salt DSC analysis of the L-tartrate salt revealed a first endothermic peak with an onset temperature of 76.4 °C and a maximum at 101.5 °C and a second endothermic peak with an onset temperature of 213.9 °C and a maximum at 216.6 °C.
  • the DSC thermogram is provided in FIG. 11.
  • Example 7 Preparation and Characterization of Compound 1 Malate Salt 64.4 mg of Compound 1 was treated with 1 mL of methanol in a 4 mL clear glass vial with stirring. To the solution/suspension, 23.0 mg of (-)-L-malic acid (1.2 eq) was added and mixed well. The resultant solution was evaporated at room temperature to dryness. The resultant solid was treated with 1 mL of methanol and stirred for 2 hours at room temperature. The solid of the malate salt was collected by filtration and air dried.
  • the salt ratio between the free base and malic acid was determined to be 1.0 by NMR analysis.
  • the malate salt was confirmed as a crystalline solid according to XRPD analysis.
  • the XRPD pattern of the malate salt is shown in FIG.13 and the peak data is given below in Table 5.
  • Example 8 Preparation and Characterization of Compound 1 Camsylate Salt 62.17 mg of Compound 1 was treated with 1 mL of methanol in a 4 mL clear glass vial with stirring.
  • XRPD Peak Data for Camsylate Salt DSC analysis of the camsylate salt revealed a first endothermic peak with an onset temperature of 21.6 °C and a maximum at 64.4 °C and a second major endothermic peak with an onset temperature of 227.2 °C and a maximum at 235.6 °C.
  • the DSC thermogram is provided in FIG.17.
  • TGA analysis of the camsylate salt revealed 0.9% weight loss below 150 °C and significant weight loss above 200 °C due to decomposition of the sample.
  • the TGA thermogram is provided in FIG.18.
  • Example 9 Preparation and Characterization of Compound 1 Mandelate Salt 65.18 mg of Compound 1 was dissolved in 1 mL of methanol in a 4 mL clear glass vial with stirring. To the solution, 26.58 mg of (S)-(+)-mandelic acid (1.2 eq) was added and mixed well. The resultant solution was evaporated at room temperature to dryness. The resultant oil was treated with 1 mL of water and stirred for 2 hours at room temperature. The solid of the mandelate salt was collected by filtration and air dried. The salt ratio between the free base and (S)-(+)-mandelic acid was determined to be 1.1 by NMR analysis. The mandelate salt was confirmed as a crystalline solid according to XRPD analysis. The XRPD pattern of the mandelate salt is shown in FIG.19 and the peak data is given below in Table 7. Table 7. XRPD Peak Data for Mandelate Salt.
  • DSC analysis of the mandelate salt revealed a first endothermic peak with an onset temperature of 81.5 °C and a maximum at 92.8 °C and a second endothermic peak with an onset temperature of 187.5 °C and a maximum at 217.4 °C.
  • the DSC thermogram is provided in FIG. 20.
  • TGA analysis of the mandelate salt revealed 4.6% weight loss below 150 °C and significant weight loss above 170 °C due to decomposition of the sample.
  • the TGA thermogram is provided in FIG.21.
  • Example 10 Preparation and Characterization of Compound 1 Citrate Salt A 2 L round bottom flask was charged with Compound 1 (59.7 g, 131 mmol) and acetone (600 mL).
  • the citrate salt was confirmed as a crystalline solid according to XRPD analysis.
  • the salt ratio between the free base and citric acid was determined to be 1.0 by NMR analysis.
  • the XRPD pattern of the citrate salt is shown in FIG.22 and the peak data is given below in Table 8. Table 8. XRPD Peak Data for Citrate Salt.
  • Example 11 Compound 2 Phosphate Salt A 3 L round bottom flask was charged with Compound 2 (21.5 g, 39.8 mmol) and acetone (1000 mL). The resulting solution was stirred at room temperature for 15 min. A solution of 1 M aqueous phosphoric acid (41.8 mL, 41.8 mmol) was added over 5 min.
  • Phosphate salt ratio was determined by 31 P NMR using triphenyl phosphate as an internal standard.
  • the phosphate salt was confirmed as a crystalline solid according to XRPD analysis.
  • the salt ratio between the free base and phosphoric acid was determined to be 1.0 by NMR analysis.
  • the XRPD pattern of the phosphate salt is shown in FIG.25 and the peak data is given below in Table 9. Table 9. XRPD Peak Data for Phosphate Salt.
  • the Compound 2 phosphate salt was characterized by DSC.
  • DSC analysis of the phosphate salt revealed one major endothermic peak with an onset temperature of 76.8 °C and a maximum at 115.5 °C and a second major endothermic peak with an onset temperature of 194.8 °C and a maximum at 199.5 °C. A small endothermic peak with a maximum at 179.7 °C was also observed.
  • the DSC thermogram is provided in FIG.26.
  • TGA analysis of the phosphate salt revealed 5.0% weight loss below 125 °C and significant weight loss above 175 °C due to decomposition of the sample. Water content was determined to be 5.2-5.3% by Karl Fischer, which suggests the phosphate salt is possibly a di- hydrate.
  • the TGA thermogram is provided in FIG.27.
  • Example 12 Compound 2 hydrochloride Salt 53.83 mg of Compound 2 free base was dissolved in 1 mL of methanol in a 4 mL clear glass vial with stirring. To the solution, 35 ⁇ L of aqueous 3M HCl (1.05 eq) was added and mixed well. The solution was evaporated without cap at room temperature to dryness. To the resulted solid, 1 mL of MeOH was added and stirred for 2 hours at room temperature. The solid of the hydrochloride salt was collected by filtration and air dried. The hydrochloride salt was confirmed as a crystalline solid according to XRPD analysis. The XRPD pattern of the hydrochloride salt is shown in FIG.28 and the peak data is given below in Table 10. Table 10.
  • the compound plate was prepared by 3-fold and 11-point serial dilutions. 0.1 ⁇ L of the compound in DMSO was transferred from the compound plate to the white 384 well polystyrene plates.
  • the assay buffer contained 50 mM HEPES, pH 7.5, 0.01% Tween-20, 5 mM MgCl 2 , 0.01% BSA, and 5 mM DTT.5 ⁇ L of 4 nM active HPK1 (SignalChem M23-11G) prepared in the buffer was added to the plate.
  • the enzyme concentration given was based on the given stock concentration reported by the vender.5 ⁇ l of 18 nM tracer 222 (ThermoFisher PV6121) and 4 nM LanthaScreen Eu-Anti GST antibody (ThermoFisher PV5595) were added. After one hour incubation at 25 o C, the plates were read on a PHERAstar FS plate reader (BMG Labtech). Ki values were determined.
  • Jurkat cells (cultured in RPMI1640 media with 10% FBS) are collected and centrifuged, followed by resuspension in appropriate media at 3 x10 6 cells / mL.
  • the Jurkat cells (35 mL) are dispensed into each well in a 384 well plate.
  • Test compounds are diluted with cell culture media for 40-fold dilution (adding 39 mL cell culture media into 1 mL compound).
  • the Jurkat cells in the well plate are treated with the test compounds at various concentrations (adding 5 ul diluted compound into 35 mL Jurkat cells and starting from 3 uM with 1:3 dilution) for 1 hour at 37 °C, 5% CO 2 ), followed by treatment with anti-CD3 (5 mg/mL, OKT3 clone) for 30 min.
  • a 1:25 dilution of 100x blocking reagent (from p-SLP76 ser376HTRF kit) with 4xLysis Buffer(LB) is prepared and 15 mL of the 4xLB buffer with blocking reagent is added into each well and incubated at room temperature for 45 min with gentle shaking.
  • the cell lysate (16 mL) is added into a Greiner white plate, treated with p-SLP76 ser376HTRF reagents (2 mL donor, 2ul acceptor) and incubated at 4 °C for overnight.
  • the homogeneous time resolved fluorescence (HTRF) is measured on a PHERAstar plate reader the next day.
  • IC 50 determination is performed by fitting the curve of percent inhibition versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.
  • Example C Isolation of CD4+ or CD8+ T Cells and Cytokine Measurement Blood samples are collected from healthy donors. CD4+ or CD8+ T cells are isolated by negative selection using CD4+ or CD8+ enrichment kits (lifetech, USA).
  • CD4+ or CD8+ T cells The purity of the isolated CD4+ or CD8+ T cells is determined by flow cytometry and is routinely >80%.
  • Cells are cultured in RPMI 1640 supplemented with 10% FCS, glutamine and antibiotics (Invitrogen Life Technologies, USA).
  • cytokine measurement Jurkat cells or primary CD4+ or CD8+ T cells are plated at 200 k cells/well and are stimulated for 24 h with anti- CD3/anti-CD28 beads in the presence or absence of testing compounds at various concentrations.16 ⁇ L of supernatants are then transferred to a white detection plate and analyzed using the human IL2 or IFNg assay kits (Cisbio).
  • Example D Treg Assay One or more compounds can be tested using the Regulatory T-cell proliferation assay described as following.
  • CD4+/CD25- T-cells and CD4+/CD25+ regulatory T-cells are isolated from human donated Peripheral Blood Mononuclear Cells, using an isolated kit from Thermo Fisher Scientific (11363D). CD4+/CD25- T-cells are labeled with CFSE (Thermo Fisher Scientific, C34554) following the protocol provided by the vendor.
  • CFSE labeled T-cells and CD4+/CD25+ regulatory T-cells are re-suspended at the concentration of 1X 106 cells/mL in RPMI-1640 medium.100 mL of CFSE-labeled T-cells are mixed with or without 50 mL of CD4+/CD25+ regulatory T-cells, treated with 5ml of anti-CD3/CD28 beads (Thermo Fisher Scientific, 11132D) and various concentrations of compounds diluted in 50ml of RPMI-1640 medium.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PCT/US2020/044919 2019-08-06 2020-08-05 Solid forms of an hpk1 inhibitor Ceased WO2021026180A1 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
PH1/2022/550271A PH12022550271A1 (en) 2019-08-06 2020-08-05 Solid forms of an hpk1 inhibitor
CR20220097A CR20220097A (es) 2019-08-06 2020-08-05 Formas sólidas de un inhibidor de hpk1
KR1020227007218A KR20220059480A (ko) 2019-08-06 2020-08-05 고체 형태의 hpk1 억제제
CA3147918A CA3147918A1 (en) 2019-08-06 2020-08-05 Solid forms of an hpk1 inhibitor
CN202080065915.4A CN114450276A (zh) 2019-08-06 2020-08-05 Hpk1抑制剂的固体形式
AU2020326703A AU2020326703A1 (en) 2019-08-06 2020-08-05 Solid forms of an HPK1 inhibitor
JP2022507441A JP2022543155A (ja) 2019-08-06 2020-08-05 Ｈｐｋ１阻害剤の固体形態
PE2022000190A PE20221419A1 (es) 2019-08-06 2020-08-05 Formas solidas de un inhibidor de hpk1
EP20760996.7A EP4010338A1 (en) 2019-08-06 2020-08-05 Solid forms of an hpk1 inhibitor
BR112022002059A BR112022002059A2 (pt) 2019-08-06 2020-08-05 Formas sólidas de um inibidor de hpk1
MX2022001562A MX2022001562A (es) 2019-08-06 2020-08-05 Formas solidas de un inhibidor de la cinasa 1 del progenitor hematopoyetico (hpk1).
IL289879A IL289879A (en) 2019-08-06 2022-01-16 Solid forms of hpk1 inhibitor
CONC2022/0002563A CO2022002563A2 (es) 2019-08-06 2022-03-03 Formas sólidas de un inhibidor de hpk1

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962883350P 2019-08-06 2019-08-06
US62/883,350 2019-08-06
US201962889848P 2019-08-21 2019-08-21
US62/889,848 2019-08-21

Publications (1)

Publication Number Publication Date
WO2021026180A1 true WO2021026180A1 (en) 2021-02-11

Family

ID=72193581

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/044919 Ceased WO2021026180A1 (en) 2019-08-06 2020-08-05 Solid forms of an hpk1 inhibitor

Country Status (18)

Country Link
US (2) US11066394B2 (https=)
EP (1) EP4010338A1 (https=)
JP (1) JP2022543155A (https=)
KR (1) KR20220059480A (https=)
CN (1) CN114450276A (https=)
AU (1) AU2020326703A1 (https=)
BR (1) BR112022002059A2 (https=)
CA (1) CA3147918A1 (https=)
CL (1) CL2022000267A1 (https=)
CO (1) CO2022002563A2 (https=)
CR (1) CR20220097A (https=)
EC (1) ECSP22015801A (https=)
IL (1) IL289879A (https=)
MX (1) MX2022001562A (https=)
PE (1) PE20221419A1 (https=)
PH (1) PH12022550271A1 (https=)
TW (1) TWI865579B (https=)
WO (1) WO2021026180A1 (https=)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11203591B2 (en) 2018-10-31 2021-12-21 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
WO2023001794A1 (en) 2021-07-20 2023-01-26 Astrazeneca Ab Substituted pyrazine-2-carboxamides as hpk1 inhibitors for the treatment of cancer
US11866426B2 (en) 2018-08-08 2024-01-09 Incyte Corporation Benzothiazole compounds and uses thereof
US11891388B2 (en) 2016-09-09 2024-02-06 Incyte Corporation Pyrazolopyridine compounds and uses thereof
US11925631B2 (en) 2018-10-31 2024-03-12 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
US12466815B2 (en) 2018-02-20 2025-11-11 Incyte Corporation Carboxamide compounds and uses thereof

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180072741A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
CN115819417A (zh) 2016-09-09 2023-03-21 因赛特公司 作为hpk1调节剂的吡唑并吡啶衍生物及其用于治疗癌症的用途
US10752635B2 (en) 2018-02-20 2020-08-25 Incyte Corporation Indazole compounds and uses thereof
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
BR112022002059A2 (pt) 2019-08-06 2022-06-07 Incyte Corp Formas sólidas de um inibidor de hpk1

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000196A2 (en) 2000-06-28 2002-01-03 Smithkline Beecham P.L.C. Wet milling process
US20070087988A1 (en) 2005-09-30 2007-04-19 New York University Hematopoietic progenitor kinase 1 for modulation of an immune response
WO2009058348A1 (en) * 2007-11-01 2009-05-07 Sirtris Pharmaceuticals, Inc. Amide derivatives as sirtuin modulators
WO2016205942A1 (en) * 2015-06-25 2016-12-29 University Health Network Hpk1 inhibitors and methods of using same
WO2019164846A1 (en) * 2018-02-20 2019-08-29 Incyte Corporation N-(phenyl)-2-(phenyl)pyrimidine-4-carboxamide derivatives and related compounds as hpk1 inhibitors for treating cancer

Family Cites Families (237)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8800613D0 (sv) 1988-02-23 1988-02-23 Wallac Oy A novel spectrofluorometric method and compounds that are of value for the method
JPH03287584A (ja) 1990-04-05 1991-12-18 Banyu Pharmaceut Co Ltd 置換アリルアミン誘導体
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
US6200980B1 (en) 1995-06-07 2001-03-13 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl purinone derivatives
US6723719B1 (en) 1997-04-25 2004-04-20 Pfizer Inc Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3′,5′—monophosphate phosphodiesterase (cGMP PDE5) for the treatment of sexual dysfunction
RS50011B (sr) 1998-04-20 2008-09-29 Pfizer Inc., Derivati piridin-3-karboksilne kiseline i njihova upotreba kao intermedijera
JP2000038350A (ja) 1998-05-18 2000-02-08 Yoshitomi Pharmaceut Ind Ltd 糖尿病治療薬
GB9823102D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
GB9823101D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
WO2001046124A1 (en) 1999-12-22 2001-06-28 Nihon Nohyaku Co., Ltd. Aromatic diamide derivatives, chemicals for agricultural or horticultural use and usage thereof
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
IN187433B (https=) 1999-09-10 2002-04-27 Cipla Ltd
WO2001019827A1 (en) 1999-09-13 2001-03-22 Cipla Ltd. A novel process for the synthesis of sildenafil citrate
MXPA02002938A (es) 1999-09-17 2004-12-06 Abbott Gmbh & Co Kg Inhibidores de cinasa como agentes agentes terapeuticos.
ES2239035T3 (es) 1999-09-24 2005-09-16 Nihon Nohyaku Co., Ltd. Derivados de diamida aromatica o sales de estos derivados, productos quimicos para la agricultura/horticultura y procedimiento de utilizacion de estos productos.
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
HK1049834A1 (zh) 1999-10-11 2003-05-30 辉瑞大药厂 用作磷酸二酯酶抑制剂的5-(2-取代的-5-杂环基磺酰基吡啶-3-基)-二氢吡唑并[4，3-d]嘧啶-7-酮类化合物
IL139073A0 (en) 1999-10-21 2001-11-25 Pfizer Treatment of neuropathy
CO5271697A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
US20020013327A1 (en) 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
AU2001277621A1 (en) 2000-08-09 2002-03-04 Astrazeneca Ab Antiangiogenic bicyclic derivatives
AU2001284417A1 (en) 2000-09-05 2002-03-22 Taisho Pharmaceutical Co. Ltd. Hair growth stimulants
US6548508B2 (en) 2000-10-20 2003-04-15 Pfizer, Inc. Use of PDE V inhibitors for improved fecundity in mammals
EP1343506A1 (de) 2000-12-19 2003-09-17 MERCK PATENT GmbH Pharmazeutische formulierung enthaltend pyrazolo 4,3-d]pyrimidine und antithrombotica, calcium-antagonisten, prostaglandine oder prostaglandinderivate
AU2002222293A1 (en) 2000-12-19 2002-07-01 Smithkline Beecham P.L.C. Pyrazolo(3,4-c)pyridines as gsk-3 inhibitors
US6784185B2 (en) 2001-03-16 2004-08-31 Pfizer Inc. Pharmaceutically active compounds
US6770645B2 (en) 2001-03-16 2004-08-03 Pfizer Inc. Pharmaceutically active compounds
US7902179B2 (en) 2001-04-26 2011-03-08 Ajinomoto Co., Inc. Heterocyclic compounds
US20040157866A1 (en) 2001-04-30 2004-08-12 Hisashi Takasugi Amide compounds
FR2825706B1 (fr) 2001-06-06 2003-12-12 Pf Medicament Nouveaux derives de benzothienyle ou d'indole, leur preparation et leur utilisation comme inhibiteurs de proteines prenyl transferase
JP2005508978A (ja) 2001-11-02 2005-04-07 ファイザー・プロダクツ・インク Ｐｄｅ９阻害薬によるインスリン抵抗性症候群及び２型糖尿病の治療
TW200303201A (en) 2001-12-10 2003-09-01 Bristol Myers Squibb Co Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones
US7166293B2 (en) 2002-03-29 2007-01-23 Carlsbad Technology, Inc. Angiogenesis inhibitors
US20050119278A1 (en) 2002-05-16 2005-06-02 Che-Ming Teng Anti-angiogenesis methods
US7429609B2 (en) 2002-05-31 2008-09-30 Eisai R & D Management Co., Ltd. Pyrazole compound and medicinal composition containing the same
EP1606289B1 (en) 2003-02-14 2009-12-02 Glaxo Group Limited Carboxamide derivatives
WO2004074286A1 (en) 2003-02-14 2004-09-02 Wyeth Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands
EP1613747A1 (en) 2003-03-31 2006-01-11 Pfizer Products Inc. Crystal structure of 3 ,5 -cyclic nucleotide phosphodiesterase 1b (pde1b) and uses thereof
OA13050A (en) 2003-04-29 2006-11-10 Pfizer Ltd 5,7-diaminopyrazolo [4,3-D] pyrimidines useful in the treatment of hypertension.
EP1628661A2 (en) 2003-06-05 2006-03-01 Vertex Pharmaceuticals Incorporated Modulators of vr1 receptor
CA2528587A1 (en) 2003-06-10 2005-01-20 Fulcrum Pharmaceuticals, Inc. .beta.-lactamase inhibitors and methods of use thereof
ZA200305330B (en) 2003-07-10 2004-05-26 Jb Chemicals & Pharmaceuticals An improved process for the preparation of 5-[2-ethoxy-5-(4-methylpiperazin-1-ylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazole[4,3-D]P yrimidin-7-one.
JP2007500700A (ja) 2003-07-29 2007-01-18 スミスクライン ビーチャム コーポレーション 化合物
TWI339206B (en) 2003-09-04 2011-03-21 Vertex Pharma Compositions useful as inhibitors of protein kinases
CN1905873A (zh) 2003-11-19 2007-01-31 阵列生物制药公司 Mek的杂环抑制剂及其使用方法
US7241773B2 (en) 2003-12-22 2007-07-10 Abbott Laboratories 3-quinuclidinyl heteroatom bridged biaryl derivatives
US20050137398A1 (en) 2003-12-22 2005-06-23 Jianguo Ji 3-Quinuclidinyl heteroatom bridged biaryl derivatives
GB0402137D0 (en) 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
DE102004005172A1 (de) 2004-02-02 2005-08-18 Aventis Pharma Deutschland Gmbh Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase
WO2005085249A1 (en) 2004-02-27 2005-09-15 F. Hoffmann-La Roche Ag Fused derivatives of pyrazole
CN1934111A (zh) 2004-02-27 2007-03-21 霍夫曼-拉罗奇有限公司 杂芳基稠合的吡唑并衍生物
JP2007526324A (ja) 2004-03-02 2007-09-13 スミスクライン・ビーチャム・コーポレイション Ａｋｔ活性のある阻害剤
TW200618800A (en) 2004-08-03 2006-06-16 Uriach Y Compania S A J Heterocyclic compounds
ES2377430T3 (es) 2004-09-02 2012-03-27 Genentech, Inc. Inhibidores piridílicos de la señalización de hedgehog
WO2006038001A1 (en) 2004-10-06 2006-04-13 Celltech R & D Limited Aminopyrimidine derivatives as jnk inhibitors
WO2006045010A2 (en) 2004-10-20 2006-04-27 Resverlogix Corp. Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
AR051596A1 (es) 2004-10-26 2007-01-24 Irm Llc Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios
EP1805136A1 (en) 2004-10-28 2007-07-11 The Institutes for Pharmaceutical Discovery, LLC Substituted phenylalkanoic acids
TW200628463A (en) 2004-11-10 2006-08-16 Synta Pharmaceuticals Corp Heteroaryl compounds
AU2005304473A1 (en) 2004-11-10 2006-05-18 Cgi Pharmaceuticals, Inc. Imidazo[1 , 2-a] pyrazin-8-ylamines useful as modulators of kinase activity
WO2006053227A2 (en) 2004-11-10 2006-05-18 Synta Pharmaceuticals Corp. Il-12 modulatory compounds
DE102004054666A1 (de) 2004-11-12 2006-05-18 Bayer Cropscience Gmbh Substituierte Pyrazol-3-carboxamide, Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
CN100516049C (zh) 2004-11-16 2009-07-22 永信药品工业股份有限公司 抗血管生成药n2-(取代的芳基甲基)-3-(取代的苯基)吲唑的合成
EP1838320B1 (en) 2005-01-07 2014-07-16 Emory University Cxcr4 antagonists for the treatment of medical disorders
JP5023054B2 (ja) 2005-03-31 2012-09-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗バクテリア剤としての二環式ピラゾール化合物
US20070032493A1 (en) 2005-05-26 2007-02-08 Synta Pharmaceuticals Corp. Method for treating B cell regulated autoimmune disorders
EP1910369A1 (en) 2005-07-29 2008-04-16 Astellas Pharma Inc. Fused heterocycles as lck inhibitors
DK1910384T3 (da) 2005-08-04 2012-12-17 Sirtris Pharmaceuticals Inc Imidazo [2,1-b] thiazol-derivater som sirtuinmodulerende forbindelser
GB0516703D0 (en) 2005-08-15 2005-09-21 Syngenta Participations Ag Novel insecticides
JP2007055940A (ja) 2005-08-24 2007-03-08 Astellas Pharma Inc ピラゾロピリミジン誘導体
KR101011956B1 (ko) 2005-08-25 2011-01-31 에프. 호프만-라 로슈 아게 Ｐ３８ ｍαｐ 키나아제 저해제 및 이의 사용 방법
CN101243051A (zh) 2005-08-25 2008-08-13 霍夫曼-拉罗奇有限公司 p38 MAP激酶抑制剂及使用它的方法
BRPI0614884A2 (pt) 2005-08-25 2011-04-19 Hoffmann La Roche inibidores de p38 map cinase e métodos para uso dos mesmos
CN101277939A (zh) 2005-09-09 2008-10-01 布里斯托尔-迈尔斯斯奎布公司 无环ikur抑制剂
EP1940296A2 (en) 2005-10-25 2008-07-09 SmithKline Beecham Corporation Chemical compounds
AU2006311766A1 (en) 2005-11-03 2007-05-18 Ilypsa, Inc. Indole compounds having C4-acidic substituents and use thereof as phospholipase-A2 inhibitors
CA2629964A1 (en) 2005-11-30 2007-06-07 Astellas Pharma Inc. 2-aminobenzamide derivative
GB0525143D0 (en) 2005-12-09 2006-01-18 Novartis Ag Organic compounds
EP1979325A1 (en) 2006-01-11 2008-10-15 AstraZeneca AB Morpholino pyrimidine derivatives and their use in therapy
US8658801B2 (en) 2006-02-16 2014-02-25 Syngenta Crop Protection, Llc Pesticides containing a bicyclic bisamide structure
AU2007230911A1 (en) 2006-03-23 2007-10-04 Synta Pharmaceuticals Corp. Benzimidazolyl-pyridine compounds for inflammation and immune-related uses
WO2007120454A1 (en) 2006-03-30 2007-10-25 Irm Llc Azolopyrimidines as inhibitors of cannabinoid 1 activity
PL2018380T3 (pl) 2006-05-19 2012-05-31 Abbvie Bahamas Ltd Skondensowane azabicykliczne pochodne alkanowe podstawione bicykloheterocyklem o aktywności wobec OUN
US20080280891A1 (en) 2006-06-27 2008-11-13 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
WO2008008059A1 (en) 2006-07-12 2008-01-17 Locus Pharmaceuticals, Inc. Anti-cancer agents ans uses thereof
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
GB0614691D0 (en) 2006-07-24 2006-08-30 Syngenta Participations Ag Insecticidal compounds
JP2010505859A (ja) 2006-10-06 2010-02-25 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤およびそれを使用するための方法
WO2008070313A2 (en) 2006-10-20 2008-06-12 Concert Pharmaceuticals Inc. 3-(dihydro-1h-pyrazolo [4,3-d] pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use
US20080194557A1 (en) 2007-01-18 2008-08-14 Joseph Barbosa Methods and compositions for the treatment of pain, inflammation and cancer
WO2008089310A2 (en) 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of obesity
CA2679659C (en) 2007-03-01 2016-01-19 Novartis Ag Pim kinase inhibitors and methods of their use
US20140249135A1 (en) * 2007-03-01 2014-09-04 Novartis Ag Pim kinase inhibitors and methods of their use
EP2002835A1 (en) 2007-06-04 2008-12-17 GenKyo Tex Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
CL2008001822A1 (es) 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras.
MY150032A (en) 2007-07-19 2013-11-29 Merck Sharp & Dohme Heterocyclic amide compounds as protein kinase inhibitors
MY146643A (en) 2007-07-30 2012-09-14 Dae Woong Pharma Novel benzoimidazole derivatives and pharmaceutical composition comprising the same
CN101790519B (zh) 2007-08-08 2013-10-16 默克雪兰诺有限公司 用于治疗多发性硬化症的结合于鞘氨醇1-磷酸(s1p)的6-氨基-嘧啶-4-羧酰胺衍生物及相关化合物
GB0716414D0 (en) 2007-08-22 2007-10-03 Syngenta Participations Ag Novel insecticides
WO2009032651A1 (en) 2007-08-31 2009-03-12 Smithkline Beecham Corporation Inhibitors of akt activity
WO2009038784A1 (en) 2007-09-21 2009-03-26 Amgen Inc. Triazole fused heteroaryl compounds as p38 kinase inhibitors
KR100963644B1 (ko) 2007-11-23 2010-06-15 한국과학기술연구원 피라졸로피리미딘온 유도체 및 그의 제조방법
CA2714181C (en) 2008-02-04 2013-12-24 Mercury Therapeutics, Inc. Ampk modulators
CN102098918A (zh) 2008-05-13 2011-06-15 帕纳德制药公司 用于治疗癌症和神经退行性疾病的生物活性化合物
CN102089278A (zh) 2008-06-11 2011-06-08 Irm责任有限公司 用于治疗疟疾的化合物和组合物
NZ603525A (en) 2008-06-27 2015-02-27 Celgene Avilomics Res Inc Pyrimidine based compound and uses thereof
WO2010029300A1 (en) 2008-09-12 2010-03-18 Biolipox Ab Bis aromatic compounds for use in the treatment of inflammation
EP2166008A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2166010A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2165707A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
WO2010046780A2 (en) 2008-10-22 2010-04-29 Institut Pasteur Korea Anti viral compounds
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ｔｔｋ阻害作用を有するインダゾール誘導体
WO2010080503A1 (en) 2008-12-19 2010-07-15 Genentech, Inc. Heterocyclic compounds and methods of use
KR20100101055A (ko) 2009-03-07 2010-09-16 주식회사 메디젠텍 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 ｇｓｋ３ 이동 관련 질환의 치료 또는 예방용 약학적 조성물
WO2010107768A1 (en) 2009-03-18 2010-09-23 Schering Corporation Bicyclic compounds as inhibitors of diacylglycerol acyltransferase
EP2411328B1 (en) 2009-03-26 2019-07-24 Northeastern University Carbon nanostructures from pyrolysis of organic materials
WO2010118367A2 (en) 2009-04-10 2010-10-14 Progenics Pharmaceuticals, Inc. Antiviral pyrimidines
US8846673B2 (en) 2009-08-11 2014-09-30 Bristol-Myers Squibb Company Azaindazoles as kinase inhibitors and use thereof
EP2477498A4 (en) 2009-09-14 2013-02-27 Merck Sharp & Dohme INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
ES2360333B1 (es) 2009-10-29 2012-05-04 Consejo Superior De Investigaciones Cientificas (Csic) (70%) Derivados de bis (aralquil) amino y sistemas (hetero) aromaticos de seis miembros y su uso en el tratamiento de patologias neurodegenerativas, incluida la enfermedad de alzheimer
JP2013032290A (ja) 2009-11-20 2013-02-14 Dainippon Sumitomo Pharma Co Ltd 新規縮合ピリミジン誘導体
WO2011078143A1 (ja) 2009-12-22 2011-06-30 塩野義製薬株式会社 ピリミジン誘導体およびそれらを含有する医薬組成物
WO2011090738A2 (en) 2009-12-29 2011-07-28 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
US20130109758A1 (en) 2010-01-06 2013-05-02 The University Of British Columbia Bisphenol derivative therapeutics and methods for their use
DE102010009903A1 (de) 2010-03-02 2011-09-08 Merck Patent Gmbh Verbindungen für elektronische Vorrichtungen
CN102206172B (zh) 2010-03-30 2015-02-25 中国医学科学院医药生物技术研究所 一组取代双芳基化合物及其制备方法和抗病毒应用
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
JP6112486B2 (ja) 2010-04-27 2017-04-12 カルシメディカ，インク． 細胞内カルシウムを調節する化合物
GB201008134D0 (en) 2010-05-14 2010-06-30 Medical Res Council Technology Compounds
JP2011246389A (ja) 2010-05-26 2011-12-08 Oncotherapy Science Ltd Ｔｔｋ阻害作用を有する縮環ピラゾール誘導体
JP2013528169A (ja) 2010-05-27 2013-07-08 バイエル・クロップサイエンス・アーゲー 殺菌剤としてのピリジニルカルボン酸誘導体
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
CN103068814B (zh) 2010-06-15 2015-11-25 拜耳知识产权有限责任公司 邻氨基苯甲酸衍生物
EP2582666B1 (en) 2010-06-16 2014-08-13 Purdue Pharma L.P. Aryl substituted indoles and their use as blockers of sodium channels
CA2806655A1 (en) 2010-07-28 2012-02-02 Bayer Intellectual Property Gmbh Substituted imidazo[1,2-b]pyridazines
US10005750B2 (en) 2010-10-06 2018-06-26 J-Pharma Co., Ltd. Developing potent urate transporter inhibitors: compounds designed for their uricosuric action
GB201017345D0 (en) 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists
CA2819373A1 (en) 2010-12-09 2012-06-14 Amgen Inc. Bicyclic compounds as pim inhibitors
CN103261188A (zh) 2010-12-17 2013-08-21 先正达参股股份有限公司 杀虫化合物
PT2661433T (pt) 2011-01-04 2017-10-24 Novartis Ag Compostos de indole ou seus análogos úteis para o tratamento da degeneração macular relacionada com a idade (amd)
EP2672820B1 (en) 2011-02-07 2019-04-17 The Washington University Mannoside compounds and methods of use thereof
EP2691399B1 (en) 2011-03-28 2016-07-13 F.Hoffmann-La Roche Ag Thiazolopyrimidine compounds
HRP20170422T1 (hr) 2011-04-12 2017-06-16 Chong Kun Dang Pharmaceutical Corp. 3-(2-aril-cikloalkenilmetil)-oksazolidin-2-on derivati kao inhibitori transportnog proteina estera kolesterola (cetp)
AP2013007253A0 (en) 2011-04-21 2013-11-30 Origenis Gmbh Pyrazolo [4,3-D] pyrimidines useful as kinase inhibitors
US9328075B2 (en) 2011-05-05 2016-05-03 St. Jude Children's Research Hospital Pyrimidinone compounds and methods for treating influenza
US20140107151A1 (en) 2011-05-17 2014-04-17 Principia Biophama Inc. Tyrosine kinase inhibitors
US20140288069A1 (en) 2011-05-17 2014-09-25 Bayer Intellectual Property Gmbh Amino-substituted imidazopyridazines as mknk1 kinase inhibitors
TW201311677A (zh) 2011-05-31 2013-03-16 Syngenta Participations Ag 殺蟲化合物
WO2012163942A1 (en) 2011-06-01 2012-12-06 Bayer Intellectual Property Gmbh Substituted aminoimidazopyridazines
WO2012175591A1 (en) 2011-06-22 2012-12-27 Bayer Intellectual Property Gmbh Heterocyclyl aminoimidazopyridazines
EP3111937B1 (en) 2011-07-08 2020-06-17 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for treatment of liver cancer
EP2543372A1 (en) 2011-07-08 2013-01-09 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for the treatment of liver cancer
AU2012293417A1 (en) 2011-08-10 2013-05-02 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
KR20140047160A (ko) 2011-08-12 2014-04-21 에프. 호프만-라 로슈 아게 인다졸 화합물, 조성물 및 사용 방법
EP2742046A1 (en) 2011-08-12 2014-06-18 F.Hoffmann-La Roche Ag PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE
WO2013042137A1 (en) 2011-09-19 2013-03-28 Aurigene Discovery Technologies Limited Bicyclic heterocycles as irak4 inhibitors
CA2849345A1 (en) 2011-09-23 2013-03-28 Bayer Intellectual Property Gmbh Substituted imidazopyridazines
CN102516263B (zh) 2011-10-25 2015-04-08 南方医科大学 一种螺三环类化合物及其制备方法、以及含该类化合物的药物组合物及其应用
CN102503959B (zh) 2011-10-25 2015-04-08 南方医科大学 一种稠三环类化合物及其制备方法、以及含该类化合物的药物组合物及其应用
KR20140095513A (ko) 2011-11-01 2014-08-01 에프. 호프만-라 로슈 아게 이미다조피리다진 화합물
AP3675A (en) 2012-02-17 2016-04-15 Kineta Four Llc Antiviral drugs for treatment of arenavirus infection
TW201348231A (zh) 2012-02-29 2013-12-01 Amgen Inc 雜雙環化合物
KR20140131955A (ko) 2012-03-09 2014-11-14 카나 바이오사이언스 인코포레이션 신규 트리아진 유도체
JP6101248B2 (ja) 2012-03-28 2017-03-22 出光興産株式会社 新規化合物、有機エレクトロルミネッセンス素子用材料および有機エレクトロルミネッセンス素子
UY34750A (es) 2012-04-20 2013-11-29 Gilead Sciences Inc ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
WO2014003405A1 (ko) 2012-06-26 2014-01-03 주식회사 제이앤드제이 캐미칼 신규한 화합물 및 이를 포함하는 발광소자
MX2014015738A (es) 2012-06-28 2015-08-06 Novartis Ag Derivados de pirrolidina y su uso como moduladores de la senda del complemento.
KR101936851B1 (ko) 2012-07-16 2019-01-11 한국과학기술연구원 단백질 키나아제 저해제인 신규 피라졸로피리딘 유도체 또는 인다졸 유도체
WO2014024125A1 (en) 2012-08-08 2014-02-13 Celon Pharma S.A. Pyrazolo[4,3-d]pyrimidin-7(6h)-one derivatives as pde9 inhibitors
TW201412744A (zh) 2012-08-23 2014-04-01 Mitsubishi Tanabe Pharma Corp 吡唑并嘧啶化合物
US9882150B2 (en) 2012-09-24 2018-01-30 Arizona Board Of Regents For And On Behalf Of Arizona State University Metal compounds, methods, and uses thereof
WO2014055955A1 (en) 2012-10-05 2014-04-10 Rigel Pharmaceuticals, Inc. Gdf-8 inhibitors
KR102137472B1 (ko) 2013-02-08 2020-07-27 삼성디스플레이 주식회사 유기 발광 소자
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
EP3495357B1 (en) 2013-03-14 2021-05-05 The Trustees of Columbia University in the City of New York 4-phenylpiperidines, their preparation and use
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
US9034927B2 (en) 2013-05-22 2015-05-19 Curza Global, Llc Methods of use for compositions comprising a biocidal polyamine
CN104232076B (zh) 2013-06-10 2019-01-15 代表亚利桑那大学的亚利桑那校董会 具有改进的发射光谱的磷光四齿金属络合物
US9718818B2 (en) 2013-08-22 2017-08-01 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
TWI652014B (zh) 2013-09-13 2019-03-01 美商艾佛艾姆希公司 雜環取代之雙環唑殺蟲劑
WO2015037965A1 (en) 2013-09-16 2015-03-19 Rohm And Haas Electronic Materials Korea Ltd. Novel organic electroluminescent compounds and organic electroluminescent device comprising the same
CA2927924A1 (en) 2013-10-18 2015-04-23 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of proliferative diseases
BR112016008632A8 (pt) 2013-10-21 2020-03-17 Merck Patent Gmbh compostos de heteroarila como inibidores de btk, seus usos, e composição farmacêutica
EP3444251B1 (en) 2013-12-11 2023-06-07 Biogen MA Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
EP3079683A4 (en) 2013-12-13 2017-12-20 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
EP3083589B1 (en) 2013-12-20 2019-12-18 Sunshine Lake Pharma Co., Ltd. Substituted piperazine compounds and methods of use thereof
EP3092226B1 (en) 2014-01-10 2019-03-13 Aurigene Discovery Technologies Limited Indazole compounds as irak4 inhibitors
JP6640098B2 (ja) 2014-02-05 2020-02-05 メルク、パテント、ゲゼルシャフト、ミット、ベシュレンクテル、ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ ＧｍｂＨ 金属錯体
US9732103B2 (en) 2014-02-25 2017-08-15 Achillion Pharmaceuticals, Inc. Carbamate, ester, and ketone compounds for treatment of complement mediated disorders
US9871208B2 (en) 2014-02-26 2018-01-16 Samsung Display Co., Ltd. Condensed cyclic compound and organic light-emitting device including the same
WO2015164956A1 (en) 2014-04-29 2015-11-05 The University Of British Columbia Benzisothiazole derivative compounds as therapeutics and methods for their use
US20150328188A1 (en) 2014-05-19 2015-11-19 Everardus O. Orlemans Combination Therapies for the Treatment of Proliferative Disorders
KR102402729B1 (ko) 2014-06-18 2022-05-26 메르크 파텐트 게엠베하 유기 전계발광 소자용 재료
WO2015193506A1 (en) 2014-06-20 2015-12-23 Institut Pasteur Korea Anti-infective compounds
AU2015275730A1 (en) 2014-06-20 2016-12-15 Aurigene Discovery Technologies Limited Substituted indazole compounds as IRAK4 inhibitors
WO2015200682A1 (en) 2014-06-25 2015-12-30 Vanderbilt University Substituted 4-alkoxypicolinamide analogs ds mglur5 negative allosteric modulators
KR20160007967A (ko) 2014-07-10 2016-01-21 삼성디스플레이 주식회사 유기 발광 소자
WO2016040184A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040181A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040188A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040180A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016041618A1 (en) 2014-09-15 2016-03-24 Merck Patent Gmbh Substituted indazoles and related heterocycles
US10253023B2 (en) 2014-10-06 2019-04-09 Merck Patent Gmbh Heteroaryl compounds as BTK inhibitors and uses thereof
JO3705B1 (ar) 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
CN107206088A (zh) 2014-12-05 2017-09-26 豪夫迈·罗氏有限公司 使用pd‑1轴拮抗剂和hpk1拮抗剂用于治疗癌症的方法和组合物
WO2016124304A1 (de) 2015-02-03 2016-08-11 Merck Patent Gmbh Metallkomplexe
EP3265445B1 (en) 2015-03-06 2021-05-05 Pharmakea, Inc. Lysyl oxidase-like 2 inhibitors and uses thereof
CN112679467B (zh) 2015-03-11 2024-11-01 Fmc公司 杂环取代的二环唑杀有害生物剂
WO2016161571A1 (en) 2015-04-08 2016-10-13 Merck Sharp & Dohme Corp. Indazole and azaindazole btk inhibitors
TW201701879A (zh) 2015-04-30 2017-01-16 拜耳製藥公司 Ｉｒａｋ４抑制劑組合
CN108024971A (zh) 2015-07-15 2018-05-11 奥列基因发现技术有限公司 作为irak-4抑制剂的取代的氮杂化合物
JP2018524372A (ja) 2015-07-15 2018-08-30 アウリジーン ディスカバリー テクノロジーズ リミテッド Ｉｒａｋ−４阻害剤としてのインダゾール及びアザインダゾール化合物
WO2017023972A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017023894A1 (en) 2015-08-03 2017-02-09 Raze Therapeutics, Inc. Mthfd2 inhibitors and uses thereof
CA2995094A1 (en) 2015-08-07 2017-02-16 Calcimedica, Inc. Use of crac channel inhibitors for the treatment of stroke and traumatic brain injury
WO2017045955A1 (en) 2015-09-14 2017-03-23 Basf Se Heterobicyclic compounds
EP3356349A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017108744A1 (de) 2015-12-22 2017-06-29 Bayer Pharma Aktiengesellschaft Neue substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
TWI726968B (zh) 2016-01-07 2021-05-11 開曼群島商Ｃｓ醫藥技術公司 Egfr酪胺酸激酶之臨床重要突變體之選擇性抑制劑
EP3492462B1 (en) 2016-07-26 2023-08-30 Shenzhen TargetRx, Inc. Amino pyrimidine compound for inhibiting protein tyrosine kinase activity
US10280164B2 (en) 2016-09-09 2019-05-07 Incyte Corporation Pyrazolopyridone compounds and uses thereof
CN115819417A (zh) 2016-09-09 2023-03-21 因赛特公司 作为hpk1调节剂的吡唑并吡啶衍生物及其用于治疗癌症的用途
US20180072741A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
WO2018049214A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
WO2018152220A1 (en) 2017-02-15 2018-08-23 Incyte Corporation Pyrazolopyridine compounds and uses thereof
US10722495B2 (en) 2017-09-08 2020-07-28 Incyte Corporation Cyanoindazole compounds and uses thereof
US10752635B2 (en) 2018-02-20 2020-08-25 Incyte Corporation Indazole compounds and uses thereof
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
GEP20227433B (en) 2018-04-26 2022-10-25 Pfizer 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors
US11633459B2 (en) 2018-05-04 2023-04-25 Novo Nordisk A/S GIP derivatives and uses thereof
EP3793559A1 (en) 2018-05-17 2021-03-24 Bayer Aktiengesellschaft Substituted dihydropyrazolo pyrazine carboxamide derivatives
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
BR112022002059A2 (pt) 2019-08-06 2022-06-07 Incyte Corp Formas sólidas de um inibidor de hpk1

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000196A2 (en) 2000-06-28 2002-01-03 Smithkline Beecham P.L.C. Wet milling process
US20070087988A1 (en) 2005-09-30 2007-04-19 New York University Hematopoietic progenitor kinase 1 for modulation of an immune response
WO2009058348A1 (en) * 2007-11-01 2009-05-07 Sirtris Pharmaceuticals, Inc. Amide derivatives as sirtuin modulators
WO2016205942A1 (en) * 2015-06-25 2016-12-29 University Health Network Hpk1 inhibitors and methods of using same
WO2019164846A1 (en) * 2018-02-20 2019-08-29 Incyte Corporation N-(phenyl)-2-(phenyl)pyrimidine-4-carboxamide derivatives and related compounds as hpk1 inhibitors for treating cancer
US20190382380A1 (en) 2018-02-20 2019-12-19 Incyte Corporation Carboxamide compounds and uses thereof

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
ALZABIN, S. ET AL., CANCER IMMUNOL IMMUNOTHER, vol. 59, no. 3, 2010, pages 419 - 29
ALZABIN, S. ET AL., J IMMUNOL, vol. 182, no. 10, 2009, pages 6187 - 94
BATLIWALLA, F.M. ET AL., MOL MED, vol. 11, no. 1-12, 2005, pages 21 - 9
DI BARTOLO, V. ET AL., J EXP MED, vol. 204, no. 3, 2007, pages 681 - 91
HU, M.C. ET AL., GENES DEV, vol. 10, no. 18, 1996, pages 2251 - 64
IKEGAMI, R. ET AL., J IMMUNOL, vol. 166, no. 7, 2001, pages 4689 - 96
KIEFER, F. ET AL., EMBO J, vol. 15, no. 24, 1996, pages 7013 - 25
LIOU, J. ET AL., IMMUNITY, vol. 12, no. 4, 2000, pages 399 - 408
SAWASDIKOSOL, S. ET AL., THE JOURNAL OF IMMUNOLOGY, vol. 188, no. 1, 2012, pages 163
SHUI, J.W. ET AL., NAT IMMUNOL, vol. 8, no. 1, 2007, pages 84 - 91
WANG, W. ET AL., J BIOL CHEM, vol. 272, no. 36, 1997, pages 22771 - 5
WANG, X. ET AL., J BIOL CHEM, vol. 287, no. 14, 2012, pages 11037 - 48
ZHOU, G. ET AL., J BIOL CHEM, vol. 274, no. 19, 1999, pages 13133 - 8

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11891388B2 (en) 2016-09-09 2024-02-06 Incyte Corporation Pyrazolopyridine compounds and uses thereof
US12516059B2 (en) 2016-09-09 2026-01-06 Incyte Corporation Pyrazolopyridine compounds and uses thereof
US12466815B2 (en) 2018-02-20 2025-11-11 Incyte Corporation Carboxamide compounds and uses thereof
US11866426B2 (en) 2018-08-08 2024-01-09 Incyte Corporation Benzothiazole compounds and uses thereof
US11203591B2 (en) 2018-10-31 2021-12-21 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
US11897878B2 (en) 2018-10-31 2024-02-13 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
US11925631B2 (en) 2018-10-31 2024-03-12 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
US12258346B2 (en) 2018-10-31 2025-03-25 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
US12037342B2 (en) 2019-05-23 2024-07-16 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
WO2023001794A1 (en) 2021-07-20 2023-01-26 Astrazeneca Ab Substituted pyrazine-2-carboxamides as hpk1 inhibitors for the treatment of cancer

Also Published As

Publication number Publication date
CO2022002563A2 (es) 2022-04-08
CL2022000267A1 (es) 2022-10-07
PH12022550271A1 (en) 2023-06-26
CN114450276A (zh) 2022-05-06
US20210040071A1 (en) 2021-02-11
CR20220097A (es) 2022-06-01
AU2020326703A1 (en) 2022-02-17
US11066394B2 (en) 2021-07-20
JP2022543155A (ja) 2022-10-07
US20220162195A1 (en) 2022-05-26
CA3147918A1 (en) 2021-02-11
IL289879A (en) 2022-03-01
KR20220059480A (ko) 2022-05-10
TW202114680A (zh) 2021-04-16
ECSP22015801A (es) 2022-05-31
MX2022001562A (es) 2022-04-26
US11787784B2 (en) 2023-10-17
EP4010338A1 (en) 2022-06-15
BR112022002059A2 (pt) 2022-06-07
PE20221419A1 (es) 2022-09-20
TWI865579B (zh) 2024-12-11

Similar Documents

Publication Publication Date Title
US11787784B2 (en) Solid forms of an HPK1 inhibitor
US12466815B2 (en) Carboxamide compounds and uses thereof
US11299473B2 (en) Benzimidazole and indole compounds and uses thereof
US10745388B2 (en) Indazole compounds and uses thereof
US11406624B2 (en) Pyrazolopyridine compounds and uses thereof
US11866426B2 (en) Benzothiazole compounds and uses thereof
US10280164B2 (en) Pyrazolopyridone compounds and uses thereof
AU2023270198B2 (en) Salts of pyrrolotriazine derivatives useful as tam inhibitors
EP3788046A1 (en) Salts of an fgfr inhibitor
US20190256520A1 (en) Indazole compounds and uses thereof
HK40042881B (en) N-(phenyl)-2-(phenyl)pyrimidine-4-carboxamide derivatives and related compounds as hpk1 inhibitors for treating cancer
HK40042881A (en) N-(phenyl)-2-(phenyl)pyrimidine-4-carboxamide derivatives and related compounds as hpk1 inhibitors for treating cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20760996

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3147918

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2022507441

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112022002059

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2020326703

Country of ref document: AU

Date of ref document: 20200805

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: NC2022/0002563

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 2020760996

Country of ref document: EP

Effective date: 20220307

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112022002059

Country of ref document: BR

Free format text: APRESENTAR A TRADUCAO SIMPLES DA FOLHA DE ROSTO DA CERTIDAO DE DEPOSITO E DA CESSAO DAS PRIORIDADES US 62/883,350 E US 62/889,848 OU DECLARACAO CONTENDO, OBRIGATORIAMENTE, TODOS OS DADOS IDENTIFICADORES DESTAS CONFORME O ART. 15 DA PORTARIA 39/2021. O DOCUMENTO APRESENTADO NAO ESTA TRADUZIDO.

WWP Wipo information: published in national office

Ref document number: NC2022/0002563

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 112022002059

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20220203

WWW Wipo information: withdrawn in national office

Ref document number: 202290492

Country of ref document: EA

WWR Wipo information: refused in national office

Ref document number: 1020227007218

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 289879

Country of ref document: IL

WWW Wipo information: withdrawn in national office

Ref document number: 784334

Country of ref document: NZ